John C. Burnett, Jr., M.D.

  1. Internist
  1. Ma X, Peddibhotla S, Zheng Y, Pan S, Mehta A, Moroni DG, Chen QY, Ma X, Burnett JC Jr, Malany S, Sangaralingham SJ. Discovery of small molecule guanylyl cyclase B receptor positive allosteric modulators. PNAS Nexus. 2024 Jun; 3 (6):pgae225 Epub 2024 June 06
    View PubMed
  2. Ma X, McKie PM, Iyer SR, Scott C, Bailey K, Johnson BK, Benike SL, Chen H, Miller WL, Cabassi A, Burnett JC Jr, Cannone V. MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease. JACC Basic Transl Sci. 2024 Jan; 9 (1):18-29 Epub 2023 Nov 01
    View PubMed
  3. Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA, Beuve A, Brouckaert P, Bryant C, Burnett JC, Farndale RW, Friebe A, Garthwaite J, Hobbs AJ, Jarvis GE, Koesling D, Kuhn M, MacEwan D, Monie TP, Potter LR, Russwurm M, Schmidt HHHW, Stasch JP, Waldman SA. The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors. Br J Pharmacol. 2023 Oct; 180 Suppl 2:S241-S288
    View PubMed
  4. Ichiki T, Cannone V, Scott CG, Iyer SR, Sangaralingham SJ, Bailey KR, Goetze JP, Tsuji Y, Rodeheffer RJ, Burnett JC Jr. Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population. Am J Physiol Heart Circ Physiol. 2023 Sep 1; 325 (3):H545-H552 Epub 2023 July 07
    View PubMed
  5. Ma X, Iyer SR, Ma X, Reginauld SH, Chen Y, Pan S, Zheng Y, Moroni DG, Yu Y, Zhang L, Cannone V, Chen HH, Ferrario CM, Sangaralingham SJ, Burnett JC Jr. Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation. Int J Mol Sci. 2023 May 10; 24 (10)
    View PubMed
  6. Sangaralingham SJ, Kuhn M, Cannone V, Chen HH, Burnett JC. Natriuretic peptide pathways in heart failure: further therapeutic possibilities. Cardiovasc Res. 2023 Feb 3; 118 (18):3416-3433
    View PubMed
  7. Chen Y, Iyer SR, Nikolaev VO, Naro F, Pellegrini M, Cardarelli S, Ma X, Lee HC, Burnett JC Jr. Manp activation of the cgmp inhibits aldosterone via pde2 and cyp11b2 in h295r cells and in mice. Hypertension. 2022 Aug; 79 (8):1702-12
  8. Chen Y, Iyer SR, Nikolaev VO, Naro F, Pellegrini M, Cardarelli S, Ma X, Lee HC, Burnett JC Jr. MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice. Hypertension. 2022 Aug; 79 (8):1702-1712 Epub 2022 June 08
    View PubMed
  9. Petraina A, Nogales C, Krahn T, Mucke H, Luscher TF, Fischmeister R, Kass DA, Burnett JC, Hobbs AJ, Schmidt HHHW. Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. Cardiovasc Res. 2022 Jul 20; 118 (9):2085-2102
    View PubMed
  10. Zhang S, Hansen DT, Martin-Garcia JM, Zook JD, Pan S, Craciunescu FM, Burnett JC Jr, Fromme P. Purification, characterization, and preliminary serial crystallography diffraction advances structure determination of full-length human particulate guanylyl cyclase A receptor. Sci Rep. 2022 Jul 12; 12 (1):11824 Epub 2022 July 12
    View PubMed
  11. Nguyen TTL, Wang M, Liu D, Iyer S, Gonzalez Bonilla HM, Acker N, Murthy V, Shrivastava S, Desai V, Burnett JC Jr, Redfield M, Bailey KR, Weinshilboum RM, Pereira NL. Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences. Circ Heart Fail 2022 Jun 3; 101161CIRCHEARTFAILURE122009629 Epub 2022 June 03
    View PubMed
  12. Dzhoyashvili NA, Iyer SR, Chen HH, Burnett JC Jr. MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension. Hypertension. 2022 Apr; 79 (4):750-760 Epub 2022 Jan 20
    View PubMed
  13. Hubers SA, Wan SH, Adel FW, Benike SL, Burnett JC Jr, Scott C, Chen HH. Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart Failure. J Am Heart Assoc. 2022 Jan 18; 11 (2):e022126 Epub 2022 Jan 08
    View PubMed
  14. Sangaralingham SJ, Whig K, Peddibhotla S, Kirby RJ, Sessions HE, Maloney PR, Hershberger PM, Mose-Yates H, Hood BL, Vasile S, Pan S, Zheng Y, Malany S, Burnett JC Jr. Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators. Proc Natl Acad Sci U S A. 2021 Dec 28; 118 (52)
    View PubMed
  15. Chen HH, Wan SH, Iyer SR, Cannone V, Sangaralingham SJ, Nuetel J, Burnett JC Jr. First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension. Hypertension. 2021 Dec; 78 (6):1859-1867 Epub 2021 Oct 18
    View PubMed
  16. Alexander SP, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Beuve A, Brouckaert P, Bryant C, Burnett JC, Farndale RW, Friebe A, Garthwaite J, Hobbs AJ, Jarvis GE, Kuhn M, MacEwan D, Monie TP, Papapetropoulos A, Potter LR, Schmidt HHHW, Szabo C, Waldman SA. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors. Br J Pharmacol. 2021 Oct; 178 Suppl 1:S264-S312
    View PubMed
  17. Ma X, Chen Y, Reginauld SH, Scott CG, Iyer SR, Schaefer JJ, Ichiki T, Chen HH, Rule AD, Burnett JC Jr, Sangaralingham SJ. Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure. JACC Heart Fail. 2021 Sep; 9 (9):613-623 Epub 2021 July 07
    View PubMed
  18. Wan SH, McKie PM, Slusser JP, Burnett JC Jr, Hodge DO, Chen HH. Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction. Physiol Rep. 2021 Aug; 9 (16):e14974
    View PubMed
  19. Cannone V, Ledwidge M, Watson C, McKie PM, Burnett JC Jr, McDonald K. STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure. JACC Basic Transl Sci. 2021 Jun; 6 (6):497-504 Epub 2021 June 16
    View PubMed
  20. Tan NY, Deng Y, Yao X, Sangaralingham LR, Shah ND, Rule AD, Burnett JC Jr, Dunlay SM, Sangaralingham SJ. Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker. Mayo Clin Proc Innov Qual Outcomes. 2021 Apr; 5 (2):286-297 Epub 2021 Feb 15
    View PubMed
  21. Ferrario CM, Iyer SR, Burnett JC Jr, Ahmad S, Wright KN, VonCannon JL, Saha A, Groban L. Angiotensin (1-12) in Humans With Normal Blood Pressure and Primary Hypertension. Hypertension. 2021 Mar 3; 77 (3):882-890 Epub 2021 Jan 19
    View PubMed
  22. Hubers SA, Schirger JA, Sangaralingham SJ, Chen Y, Burnett JC Jr, Hodge D, Chen HH. B-type natriuretic peptide and cardiac remodelling after myocardial infarction: a randomised trial. Heart. 2021 Mar; 107 (5):396-402 Epub 2020 Aug 03
    View PubMed
  23. Murphy SP, Prescott MF, Camacho A, Iyer SR, Maisel AS, Felker GM, Butler J, Pina IL, Ibrahim NE, Abbas C, Burnett JC Jr, Solomon SD, Januzzi JL. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2021 Feb; 9 (2):127-136 Epub 2020 Nov 11
    View PubMed
  24. Cannone V, Burnett JC Jr. Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension. Front Physiol. 2021; 12:815796 Epub 2022 Feb 11
    View PubMed
  25. Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J Jr, Parker J, Seferovic JP, Wilson P, Mittleman RS, Profy AT, Konstam MA. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. JAMA. 2020 Oct 20; 324 (15):1522-1531
    View PubMed
  26. Savira F, Magaye R, Liew D, Reid C, Kelly DJ, Kompa AR, Sangaralingham SJ, Burnett JC Jr, Kaye D, Wang BH. Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature. Br J Pharmacol. 2020 Jul; 177 (13):2906-2922 Epub 2020 May 13
    View PubMed
  27. Ibrahim NE, Burnett JC Jr, Butler J, Camacho A, Felker GM, Fiuzat M, O'Connor C, Solomon SD, Vaduganathan M, Zile MR, Januzzi JL Jr. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. JACC Heart Fail. 2020 May; 8 (5):347-358 Epub 2020 Mar 11
    View PubMed
  28. Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J Jr, Mittleman RS, Profy AT, Seferovic JP, Reasner D, Konstam MA. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 Apr; 222:183-190 Epub 2020 Jan 21
    View PubMed
  29. Chen Y, Schaefer JJ, Iyer SR, Harders GE, Pan S, Sangaralingham SJ, Chen HH, Redfield MM, Burnett JC Jr. Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP. Am J Physiol Regul Integr Comp Physiol. 2020 Apr 1; 318 (4):R669-R676 Epub 2020 Feb 05
    View PubMed
  30. Sangaralingham SJ, Chen Y, Burnett JC. C-type natriuretic peptide: the heart's guardian angel. Eur Heart J 2020 Mar 1; 41 (9):1021-1023
    View PubMed
  31. Lyle MA, Iyer SR, Redfield MM, Reddy YNV, Felker GM, Cappola TP, Hernandez AF, Hernandez A, Scott CG, Burnett JC Jr, Pereira NL. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2020 Jan; 8 (1):70-80 Epub 2019 Aug 07
    View PubMed
  32. Spannella F, Giulietti F, Bordicchia M, Burnett JC Jr, Sarzani R. Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis. Sci Rep. 2019 Dec 16; 9 (1):19178
    View PubMed
  33. Burnett JC Jr. Atrial Natriuretic Peptide, Heart Failure and the Heart as an Endocrine Organ. Clin Chem. 2019 Dec; 65 (12):1602-1603 Epub 2019 July 30
    View PubMed
  34. Wan SH, Torres-Courchoud I, McKie PM, Slusser JP, Redfield MM, Burnett JC Jr, Hodge DO, Chen HH. Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP. JACC Basic Transl Sci. 2019 Dec; 4 (8):962-972 Epub 2019 Dec 23
    View PubMed
  35. Yang S, Huang S, Daniels LB, Yeboah J, Lima JAC, Cannone V, Burnett JC Jr, Beckman JA, Carr JJ, Wang TJ, Gupta DK. NT-proBNP, race and endothelial function in the Multi-Ethnic Study of Atherosclerosis. Heart. 2019 Oct; 105 (20):1590-1596 Epub 2019 May 31
    View PubMed
  36. Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC Jr, Llorens-Cortes C, Ehlers MR, Sturrock ED. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev. 2019 Oct; 71 (4):539-570
    View PubMed
  37. Reginauld SH, Cannone V, Iyer S, Scott C, Bailey K, Schaefer J, Chen Y, Sangaralingham SJ, Burnett JC Jr. Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP. JACC Heart Fail. 2019 Oct; 7 (10):891-898 Epub 2019 Sept 11
    View PubMed
  38. Hansen LH, Madsen TD, Goth CK, Clausen H, Chen Y, Dzhoyashvili N, Iyer SR, Sangaralingham SJ, Burnett JC Jr, Rehfeld JF, Vakhrushev SY, Schjoldager KT, Goetze JP. Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor. J Biol Chem. 2019 Aug 23; 294 (34):12567-12578 Epub 2019 June 11
    View PubMed
  39. Reddy YNV, Iyer SR, Scott CG, Rodeheffer RJ, Bailey K, Jenkins G, Batzler A, Redfield MM, Burnett JC Jr, Pereira NL. Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease. J Am Heart Assoc. 2019 Aug 6; 8 (15):e012943 Epub 2019 July 26
    View PubMed
  40. Cannone V, Cabassi A, Volpi R, Burnett JC, Jr. Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease. Int J Mol Sci. 2019 Jul 2; 20 (13) Epub 2019 July 02
    View PubMed
  41. Chen Y, Harty GJ, Zheng Y, Iyer SR, Sugihara S, Sangaralingham SJ, Ichiki T, Grande JP, Lee HC, Wang XL, Burnett JC Jr. CRRL269. Circ Res. 2019 May 10; 124 (10):1462-1472
    View PubMed
  42. Chen Y, Zheng Y, Iyer SR, Harders GE, Pan S, Chen HH, Ichiki T, Burnett JC Jr, Sangaralingham SJ. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. J Mol Cell Cardiol. 2019 May; 130:140-150 Epub 2019 Apr 04
    View PubMed
  43. Ichiki T, Dzhoyashvili N, Burnett JC Jr. Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. Int J Cardiol. 2019 Apr 15; 281:166-171 Epub 2018 June 03
    View PubMed
  44. Meems LMG, Andersen IA, Pan S, Harty G, Chen Y, Zheng Y, Harders GE, Ichiki T, Heublein DM, Iyer SR, Sangaralingham SJ, McCormick DJ, Burnett JC Jr. Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide. Hypertension. 2019 Apr; 73 (4):900-909
    View PubMed
  45. Bachmann KN, Huang S, Lee H, Dichtel LE, Gupta DK, Burnett JC Jr, Miller KK, Wang TJ, Finkelstein JS. Effect of Testosterone on Natriuretic Peptide Levels. J Am Coll Cardiol. 2019 Mar 26; 73 (11):1288-1296
    View PubMed
  46. Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, Apple FS, Burnett JC Jr, Iyer S, Januzzi JL Jr. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol. 2019 Mar 26; 73 (11):1273-1284
    View PubMed
  47. Bartels ED, Guo S, Kousholt BS, Larsen JR, Hasenkam JM, Burnett J Jr, Nielsen LB, Ashina M, Goetze JP. High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs. Peptides. 2019 Feb; 112:43-47 Epub 2018 Nov 30
    View PubMed
  48. Oatmen KE, Zile MR, Burnett JC Jr, Spinale FG. Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. JAMA Cardiol. 2018 Dec 1; 3 (12):1232-1243
    View PubMed
  49. Kawakami R, Lee CYW, Scott C, Bailey KR, Schirger JA, Chen HH, Benike SL, Cannone V, Martin FL, Sangaralingham SJ, Ichiki T, Burnett JC Jr. A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. Clin Pharmacol Ther. 2018 Sep; 104 (3):546-552 Epub 2018 Jan 11
    View PubMed
  50. Cannone V, Buglioni A, Sangaralingham SJ, Scott C, Bailey KR, Rodeheffer R, Redfield MM, Sarzani R, Burnett JC Jr. Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. Mayo Clin Proc. 2018 Aug; 93 (8):980-990
    View PubMed
  51. Chen Y, Burnett JC. Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications. Int J Mol Sci. 2018 Mar 27; 19 (4)
    View PubMed
  52. Chen Y, Harty GJ, Huntley BK, Iyer SR, Heublein DM, Harders GE, Meems L, Pan S, Sangaralingham SJ, Ichiki T, Burnett JC Jr. CRRL269: a novel designer and renal-enhancing pGC-A peptide activator. Am J Physiol Regul Integr Comp Physiol. 2018 Mar 1; 314 (3):R407-R414 Epub 2017 Nov 29
    View PubMed
  53. Gupta DK, Daniels LB, Cheng S, deFilippi CR, Criqui MH, Maisel AS, Lima JA, Bahrami H, Greenland P, Cushman M, Tracy R, Siscovick D, Bertoni AG, Cannone V, Burnett JC, Carr JJ, Wang TJ. Differences in Natriuretic Peptide Levels by Race/Ethnicity (From the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2017 Sep 15; 120 (6):1008-1015 Epub 2017 June 30
    View PubMed
  54. Sugihara S, Burnett JC Jr. BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning? Eur Heart J 2017 Aug 7; 38 (30):2374-2376
    View PubMed
  55. Saiki H, Moulay G, Guenzel AJ, Liu W, Decklever TD, Classic KL, Pham L, Chen HH, Burnett JC, Russell SJ, Redfield MM. Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2017 Aug 1; 313 (2):H392-H407 Epub 2017 May 26
    View PubMed
  56. Ichiki T, Burnett JC Jr. Atrial Natriuretic Peptide- Old But New Therapeutic in Cardiovascular Diseases. Circ J. 2017 Jun 23; 81 (7):913-919 Epub 2017 May 27
    View PubMed
  57. Ichiki T, Huntley BK, Harty GJ, Sangaralingham SJ, Burnett JC Jr. Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling. Physiol Rep. 2017 May; 5 (9) Epub 2017 May 15
    View PubMed
  58. Ichiki T, Burnett JC Jr, Scott CG, Heublein DM, Miyata M, Kinugawa K, Inoue T, Tei C, WAON-CHF Study Investigators. Neurohumoral Modulation During Waon Therapy in Chronic Heart Failure- Subanalysis of Waon-CHF Study. Circ J. 2017 Apr 25; 81 (5):709-716 Epub 2017 Feb 16
    View PubMed
  59. Glode A, Naumann J, Gnad T, Cannone V, Kilic A, Burnett JC Jr, Pfeifer A. Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolism. Mol Metab. 2017 Mar; 6 (3):276-287 Epub 2017 Jan 04
    View PubMed
  60. Chen Y, Burnett JC Jr. Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease. Clin Chem. 2017 Jan; 63 (1):108-115 Epub 2016 Nov 15
    View PubMed
  61. Cannone V, Scott CG, Decker PA, Larson NB, Palmas W, Taylor KD, Wang TJ, Gupta DK, Bielinski SJ, Burnett JC Jr. A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One. 2017; 12 (12):e0189858 Epub 2017 Dec 18
    View PubMed
  62. Meems LMG, Burnett JC Jr. Innovative Therapeutics: Designer Natriuretic Peptides. JACC Basic Transl Sci. 2016 Dec; 1 (7):557-567
    View PubMed
  63. AbouEzzeddine OF, McKie PM, Scott CG, Rodeheffer RJ, Chen HH, Michael Felker G, Jaffe AS, Burnett JC, Redfield MM. Biomarker-based risk prediction in the community. Eur J Heart Fail. 2016 Nov; 18 (11):1342-1350
    View PubMed
  64. Wan SH, McKie PM, Schirger JA, Slusser JP, Hodge DO, Redfield MM, Burnett JC Jr, Chen HH. Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure). JACC Heart Fail. 2016 Jul; 4 (7):539-547 Epub 2016 Feb 10
    View PubMed
  65. Bordicchia M, Ceresiani M, Pavani M, Minardi D, Polito M, Wabitsch M, Cannone V, Burnett JC Jr, Dessi-Fulgheri P, Sarzani R. Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway. Am J Physiol Regul Integr Comp Physiol. 2016 Jul 1; 311 (1):R104-14 Epub 2016 Apr 13
    View PubMed
  66. Grupper A, Zhao YM, Sajgalik P, Joyce LD, Park SJ, Pereira NL, Stulak JM, Burnett JC Jr, Edwards BS, Daly RC, Kushwaha SS, Schirger JA. Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation. Am J Cardiol. 2016 Jun 1; 117 (11):1765-70 Epub 2016 Mar 18
    View PubMed
  67. Holditch SJ, Schreiber CA, Burnett JC, Ikeda Y. Arterial Remodeling in B-Type Natriuretic Peptide Knock-Out Females. Sci Rep. 2016 May 10; 6:25623
    View PubMed
  68. Andersen IA, Huntley BK, Sandberg SS, Heublein DM, Burnett JC Jr. Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant. 2016 May; 31 (5):767-72 Epub 2015 Dec 13
    View PubMed
  69. Hiemstra JA, Lee DI, Chakir K, Gutierrez-Aguilar M, Marshall KD, Zgoda PJ, Cruz Rivera N, Dozier DG, Ferguson BS, Heublein DM, Burnett JC, Scherf C, Ivey JR, Minervini G, McDonald KS, Baines CP, Krenz M, Domeier TL, Emter CA. Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine. J Am Heart Assoc. 2016 Apr 20; 5 (4):e003277
    View PubMed
  70. McKie PM, Schirger JA, Benike SL, Harstad LK, Slusser JP, Hodge DO, Redfield MM, Burnett JC Jr, Chen HH. Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail. 2016 Apr; 18 (4):433-41 Epub 2016 Jan 24
    View PubMed
  71. Lee CY, Huntley BK, McCormick DJ, Ichiki T, Sangaralingham SJ, Lisy O, Burnett JC Jr. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharmacother. 2016 Apr; 2 (2):98-105 Epub 2015 Dec 10
    View PubMed
  72. Sangaralingham SJ, Wang BH, Huang L, Kumfu S, Ichiki T, Krum H, Burnett JC Jr. Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen. Peptides. 2016 Feb; 76:108-14 Epub 2016 Jan 13
    View PubMed
  73. Huang Y, Ng XW, Lim SG, Chen HH, Burnett JC Jr, Boey YC, Venkatraman SS. In vivo Evaluation of Cenderitide-Eluting Stent (CES) II. Ann Biomed Eng. 2016 Feb; 44 (2):432-41 Epub 2015 July 16
    View PubMed
  74. Buglioni A, Burnett JC Jr. New Pharmacological Strategies to Increase cGMP. Annu Rev Med. 2016; 67:229-43 Epub 2015 Oct 14
    View PubMed
  75. Buglioni A, Cannone V, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Sarzani R, Burnett JC. Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up. J Am Heart Assoc. 2015 Dec 23; 4 (12)
    View PubMed
  76. Guo S, Goetze JP, Jeppesen JL, Burnett JC, Olesen J, Jansen-Olesen I, Ashina M. Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. Peptides. 2015 Dec; 74:33-42.
    View PubMed
  77. Ichiki T, Huntley BK, Sangaralingham SJ, Burnett JC Jr. Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides. JACC Heart Fail. 2015 Sep; 3 (9):715-23
    View PubMed
  78. Holditch SJ, Schreiber CA, Nini R, Tonne JM, Peng KW, Geurts A, Jacob HJ, Burnett JC, Cataliotti A, Ikeda Y. B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension. Hypertension. 2015 Jul; 66 (1):199-210 Epub 2015 May 11
    View PubMed
  79. Sangaralingham SJ, McKie PM, Ichiki T, Scott CG, Heublein DM, Chen HH, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population. Hypertension. 2015 Jun; 65 (6):1187-94 Epub 2015 Apr 20
    View PubMed
  80. Buglioni A, Burnett JC Jr. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta. 2015 Mar 30; 443:3-8 Epub 2014 Oct 23
    View PubMed
  81. Zakeri R, Burnett JC Jr, Sangaralingham SJ. Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodeling. Clin Chim Acta. 2015 Mar 30; 443:108-13 Epub 2014 Dec 12
    View PubMed
  82. Pereira NL, Tosakulwong N, Scott CG, Jenkins GD, Prodduturi N, Chai Y, Olson TM, Rodeheffer RJ, Redfield MM, Weinshilboum RM, Burnett JC. Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with stroke in whites. Circ Cardiovasc Genet. 2015 Feb; 8 (1):141-9 Epub 2014 Dec 01
    View PubMed
  83. McKie PM, Burnett JC Jr. Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure. Curr Heart Fail Rep. 2015 Feb; 12 (1):7-14
    View PubMed
  84. Arora P, Reingold J, Baggish A, Guanaga DP, Wu C, Ghorbani A, Song Y, Chen-Tournaux A, Khan AM, Tainsh LT, Buys ES, Williams JS, Heublein DM, Burnett JC, Semigran MJ, Bloch KD, Scherrer-Crosbie M, Newton-Cheh C, Kaplan LM, Wang TJ. Weight loss, saline loading, and the natriuretic peptide system. J Am Heart Assoc. 2015 Jan 16; 4 (1):e001265
    View PubMed
  85. Bellavia D, Cataliotti A, Clemenza F, Baravoglia CH, Luca A, Traina M, Gridelli B, Bertani T, Burnett JC, Scardulla C. Long-Term Structural and Functional Myocardial Adaptations in Healthy Living Kidney Donors: A Pilot Study. PLoS One. 2015; 10 (11):e0142103 Epub 2015 Nov 10
    View PubMed
  86. Huntley BK, Sandberg SM, Heublein DM, Sangaralingham SJ, Burnett JC Jr, Ichiki T. Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure. Circ Heart Fail. 2015 Jan; 8 (1):89-97 Epub 2014 Oct 22
    View PubMed
  87. Miller WL, Borgeson DD, Grantham JA, Luchner A, Redfield MM, Burnett JC Jr. Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure. Eur J Heart Fail. 2015; 17(2):144-50.
    View PubMed
  88. Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dessi-Fulgheri P, Sarzani R, Burnett JC Jr. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension. 2015 Jan; 65 (1):45-53 Epub 2014 Nov 03
    View PubMed
  89. Ng XW, Huang Y, Liu KL, Lim SG, Chen HH, Burnett JC Jr, Freddy Boey YC, Venkatraman SS. In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach. J Pharm Sci. 2014 Nov; 103 (11):3631-3640 Epub 2014 Sept 15
    View PubMed
  90. Ichiki T, Schirger JA, Huntley BK, Brozovich FV, Maleszewski JJ, Sandberg SM, Sangaralingham SJ, Park SJ, Burnett JC Jr. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications. J Mol Cell Cardiol. 2014 Oct; 75:199-205 Epub 2014 Aug 09
    View PubMed
  91. McKie PM, AbouEzzeddine OF, Scott CG, Mehta R, Rodeheffer RJ, Redfield MM, Burnett JC Jr, Jaffe AS. High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population. Clin Chem. 2014 Sep; 60 (9):1225-33 Epub 2014 July 01
    View PubMed
  92. Gruson D, Buglioni A, Burnett JC Jr. PTH: Potential role in management of heart failure. Clin Chim Acta. 2014 Jun 10; 433:290-6 Epub 2014 Apr 01
    View PubMed
  93. Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: time for a new approach? Circ Heart Fail. 2014 May; 7 (3):531-5
    View PubMed
  94. McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC Jr. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc. 2014 Jan 2; 3 (1):e000206 Epub 2014 Jan 02
    View PubMed
  95. Pan S, Chen HH, Correia C, Dai H, Witt TA, Kleppe LS, Burnett JC Jr, Simari RD. Cell surface protein disulfide isomerase regulates natriuretic peptide generation of cyclic guanosine monophosphate. PLoS One. 2014; 9(11):e112986. Epub 2014 Nov 24.
    View PubMed
  96. Pereira NL, Redfield MM, Scott C, Tosakulwong N, Olson TM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. A functional genetic variant (N521D) in natriuretic peptide receptor 3 is associated with diastolic dysfunction: the prevalence of asymptomatic ventricular dysfunction study. PLoS One. 2014; 9 (1):e85708 Epub 2014 Jan 22
    View PubMed
  97. Volpe M, Rubattu S, Burnett J. Natriuretic peptides in cardiovascular diseases: Current use and perspectives. Eur Heart J. 2014; 35(7):419-25c.
    View PubMed
  98. Greene SJ, Gheorghiade M, Borlaug BA, Pieske B, Vaduganathan M, Burnett JC Jr, Roessig L, Stasch JP, Solomon SD, Paulus WJ, Butler J. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc. 2013 Dec; 2(6):e000536. Epub 2013 Dec 11.
    View PubMed
  99. Cannone V, Huntley BK, Olson TM, Heublein DM, Scott CG, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension. 2013 Nov; 62 (5):860-5 Epub 2013 Sept 16
    View PubMed
  100. Ichiki T, Izumi R, Cataliotti A, Larsen AM, Sandberg SM, Burnett JC Jr. Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis. Peptides. 2013 Oct; 48:21-6 Epub 2013 Aug 06
    View PubMed
  101. Violin JD, Soergel DG, Boerrigter G, Burnett JC Jr, Lark MW. GPCR biased ligands as novel heart failure therapeutics. Trends Cardiovasc Med. 2013 Oct; 23(7):242-9. Epub 2013 Mar 15.
    View PubMed
  102. Cannone V, Cefalu' AB, Noto D, Scott CG, Bailey KR, Cavera G, Pagano M, Sapienza M, Averna MR, Burnett JC Jr. The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population. Diabetes Care. 2013 Sep; 36 (9):2850-6 Epub 2013 May 01
    View PubMed
  103. Sangaralingham SJ, Burnett JC Jr, McKie PM, Schirger JA, Chen HH. Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction. J Card Fail. 2013 Aug; 19 (8):533-9
    View PubMed
  104. McKie PM, Heublein DM, Scott CG, Gantzer ML, Mehta RA, Rodeheffer RJ, Redfield MM, Burnett JC Jr, Jaffe AS. Defining high-sensitivity cardiac troponin concentrations in the community. Clin Chem. 2013 Jul; 59 (7):1099-107 Epub 2013 Apr 16
    View PubMed
  105. Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE, Everest Investigators. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail. 2013 Jun; 19(6):390-7. Epub 2013 May 14
    View PubMed
  106. Costello-Boerrigter LC, Lapp H, Boerrigter G, Lerman A, Bufe A, Macheret F, Heublein DM, Larue C, Burnett JC Jr. Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure. JACC Heart Fail. 2013 Jun; 1 (3):207-12 Epub 2013 June 03
    View PubMed
  107. von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC Jr, Krum H. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013 May; 6(3):594-605.
    View PubMed
  108. Pereira NL, Lin D, Pelleymounter L, Moon I, Stilling G, Eckloff BW, Wieben ED, Redfield MM, Burnett JC Jr, Yee VC, Weinshilboum RM. Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation. Circ Cardiovasc Genet. 2013 Apr; 6 (2):201-10 Epub 2013 Mar 14
    View PubMed
  109. Zakeri R, Sangaralingham SJ, Sandberg SM, Heublein DM, Scott CG, Burnett JC Jr. Urinary C-type natriuretic peptide: a new heart failure biomarker. JACC Heart Fail. 2013 Apr; 1 (2):170-7
    View PubMed
  110. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013 Mar; 34 (12):886-893c Epub 2012 Aug 31
    View PubMed
  111. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M, EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013 Mar; 34(11):835-43. Epub 2013 Jan 4
    View PubMed
  112. Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, Burnett JC, Campia U, Cleland JG, Collins SP, Fonarow GC, Levy PD, Metra M, Pitt B, Ponikowski P, Sato N, Voors AA, Stasch JP, Butler J, Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013 Mar; 18(2):123-34.
    View PubMed
  113. Ichiki T, Boerrigter G, Huntley BK, Sangaralingham SJ, McKie PM, Harty GJ, Harders GE, Burnett JC Jr. Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15; 304 (2):R102-9 Epub 2012 Nov 14
    View PubMed
  114. Lim SG, Venkatraman SS, Burnett JC Jr, Chen HH. In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. PLoS One. 2013; 8(2):e52484. Epub 2013 Feb 18.
    View PubMed
  115. Ichiki T, Huntley BK, Burnett JC Jr. BNP molecular forms and processing by the cardiac serine protease corin. Adv Clin Chem. 2013; 61:1-31
    View PubMed
  116. Ng XW, Huang Y, Chen HH, Burnett JC Jr, Boey FY, Venkatraman SS. Cenderitide-eluting film for potential cardiac patch applications. PLoS One. 2013; 8(7):e68346. Epub 2013 Jul 04.
    View PubMed
  117. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012 Dec 4; 60 (22):2305-12 Epub 2012 Nov 01
    View PubMed
  118. Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J Jr, Cataliotti A. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012 Oct 16; 60 (16):1558-65
    View PubMed
  119. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr. TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail. 2012 Sep 1; 5 (5):627-34 Epub 2012 Aug 13
    View PubMed
  120. Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP, EVEREST investigators. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown). 2012 Jul; 13(7):415-22.
    View PubMed
  121. Sangaralingham SJ, Ritman EL, McKie PM, Ichiki T, Lerman A, Scott CG, Martin FL, Harders GE, Bellavia D, Burnett JC Jr. Cardiac micro-computed tomography imaging of the aging coronary vasculature. Circ Cardiovasc Imaging. 2012 Jul; 5 (4):518-24 Epub 2012 June 07
    View PubMed
  122. Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012 May; 17(3):485-509.
    View PubMed
  123. Mohammed SF, Storlie JR, Oehler EA, Bowen LA, Korinek J, Lam CS, Simari RD, Burnett JC Jr, Redfield MM. Variable phenotype in murine transverse aortic constriction. Cardiovasc Pathol. 2012 May-Jun; 21 (3):188-98 Epub 2011 July 18
    View PubMed
  124. McKie PM, Ichiki T, Burnett JC Jr. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012 Feb; 14 (1):62-9
    View PubMed
  125. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15; 302 (2):R292-9 Epub 2011 Nov 09
    View PubMed
  126. Martin FL, Sangaralingham SJ, Huntley BK, McKie PM, Ichiki T, Chen HH, Korinek J, Harders GE, Burnett JC Jr. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One. 2012; 7 (12):e52422 Epub 2012 Dec 18
    View PubMed
  127. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC Jr, Linke WA, Redfield MM. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation. 2011 Dec 20; 124 (25):2882-91 Epub 2011 Dec 05
    View PubMed
  128. McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc. 2011 Dec; 86 (12):1154-60
    View PubMed
  129. McKie PM, Schirger JA, Costello-Boerrigter LC, Benike SL, Harstad LK, Bailey KR, Hodge DO, Redfield MM, Simari RD, Burnett JC Jr, Chen HH. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol. 2011 Nov 8; 58 (20):2095-103
    View PubMed
  130. Sangaralingham SJ, Heublein DM, Grande JP, Cataliotti A, Rule AD, McKie PM, Martin FL, Burnett JC Jr. Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. Am J Physiol Renal Physiol. 2011 Nov; 301 (5):F943-52 Epub 2011 Aug 24
    View PubMed
  131. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC Jr. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail. 2011 Nov; 4 (6):770-8 Epub 2011 Aug 11
    View PubMed
  132. Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M, EVEREST Investigators. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011 Oct; 32(20):2563-72. Epub 2011 Jul 23.
    View PubMed
  133. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011 Aug 24; 306 (8):856-63
    View PubMed
  134. Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, Heublein DM, Lahr BD, Bailey KR, Averna M, Redfield MM, Rodeheffer RJ, Burnett JC Jr. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011 Aug 2; 58 (6):629-36
    View PubMed
  135. Zakeri R, Burnett JC. Designer natriuretic peptides: a vision for the future of heart failure therapeutics. Can J Physiol Pharmacol. 2011 Aug; 89(8):593-601. Epub 2011 Aug 04.
    View PubMed
  136. Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC Jr, Ouyang J, Udelson JE, Konstam MA. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. Am Heart J. 2011 Jun; 161(6):1067-72.
    View PubMed
  137. Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, Macheret F, Huntley BK, Burnett JC Jr, Ikeda Y. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem. 2011 Jun; 57 (6):864-73 Epub 2011 Apr 11
    View PubMed
  138. Costello-Boerrigter LC, Burnett JC Jr. Heart failure: furosemide--to DOSE or not to DOSE, that is the question. Nat Rev Cardiol. 2011 May 31; 8 (7):365-6
    View PubMed
  139. Dong YX, Burnett JC Jr, Chen HH, Sandberg S, Yang YZ, Zhang Y, Chen PS, Cha YM. Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure. J Interv Card Electrophysiol. 2011 Apr; 30 (3):241-9 Epub 2011 Feb 19
    View PubMed
  140. Bellavia D, Abraham RS, Pellikka PA, Dispenzieri A, Burnett JC Jr, Al-Zahrani GB, Green TD, Manske MK, Gertz MA, Miller FA Jr, Abraham TP. Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al). J Am Soc Echocardiogr. 2011 Apr; 24 (4):444-54 Epub 2011 Feb 18
    View PubMed
  141. Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, Campbell JM, Peng KW, Russell SJ, Malatino LS, Burnett JC Jr, Ikeda Y. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011 Mar 29; 123 (12):1297-305 Epub 2011 Mar 14
    View PubMed
  142. Macheret F, Boerrigter G, McKie P, Costello-Boerrigter L, Lahr B, Heublein D, Sandberg S, Ikeda Y, Cataliotti A, Bailey K, Rodeheffer R, Burnett JC Jr. Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2011 Mar 22; 57 (12):1386-95
    View PubMed
  143. Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, Mahoney DW, Slusser JP, Heublein DM, Redfield MM, Rodeheffer RJ, Olson TM, Burnett JC Jr. The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc. 2011 Mar; 86 (3):210-8
    View PubMed
  144. Sangaralingham SJ, Huntley BK, Martin FL, McKie PM, Bellavia D, Ichiki T, Harders GE, Chen HH, Burnett JC Jr. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension. 2011 Feb; 57 (2):201-7 Epub 2010 Dec 28
    View PubMed
  145. Ichiki T, Huntley BK, Heublein DM, Sandberg SM, McKie PM, Martin FL, Jougasaki M, Burnett JC Jr. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem. 2011 Jan; 57 (1):40-7 Epub 2010 Nov 12
    View PubMed
  146. Shuford CM, Hawkridge AM, Burnett JC, Muddiman DC. Utilizing spectral counting to quantitatively characterize tandem removal of abundant proteins (TRAP) in human plasma. Anal Chem. 2010 Dec 15; 82(24):10179-85. Epub 2010 Nov 19.
    View PubMed
  147. Kilic A, Rajapurohitam V, Sandberg SM, Zeidan A, Hunter JC, Said Faruq N, Lee CY, Burnett JC Jr, Karmazyn M. A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway. Cardiovasc Res. 2010 Dec 1; 88(3):434-42. Epub 2010 Aug 02.
    View PubMed
  148. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T, Burnett JC Jr. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010 Dec; 56 (6):1152-9 Epub 2010 Oct 25
    View PubMed
  149. Pereira NL, Aksoy P, Moon I, Peng Y, Redfield MM, Burnett JC Jr, Wieben ED, Yee VC, Weinshilboum RM. Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol. 2010 Nov; 49 (5):864-74 Epub 2010 Aug 06
    View PubMed
  150. Huntley BK, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC Jr. B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. J Cell Physiol. 2010 Oct; 225 (1):251-5
    View PubMed
  151. McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep. 2010 Sep; 7 (3):93-9
    View PubMed
  152. Boilson BA, Larsen K, Harbuzariu A, Delacroix S, Korinek J, Froehlich H, Bailey KR, Scott CG, Shapiro BP, Boerrigter G, Chen HH, Redfield MM, Burnett JC Jr, Simari RD. Regulation of circulating progenitor cells in left ventricular dysfunction. Circ Heart Fail. 2010 Sep; 3 (5):635-42 Epub 2010 June 23
    View PubMed
  153. Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, Collins S, Diercks D, Fonarow G, Hollander J, Kellerman A, Gheorghiade M, Kirk D, Levy P, Maisel A, Massie BM, O'Connor C, Pang P, Shah M, Sopko G, Stevenson L, Storrow A, Teerlink J. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. J Am Coll Cardiol. 2010 Jul 27; 56(5):343-51.
    View PubMed
  154. Mohammed SF, Ohtani T, Korinek J, Lam CS, Larsen K, Simari RD, Valencik ML, Burnett JC Jr, Redfield MM. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation. 2010 Jul 27; 122 (4):370-8 Epub 2010 July 12
    View PubMed
  155. McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010 May 11; 55 (19):2140-7
    View PubMed
  156. Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JC Jr. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ Heart Fail. 2010 May; 3 (3):412-9 Epub 2010 Feb 22
    View PubMed
  157. Correa de Sa DD, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC, Chen HH. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart. 2010 Apr; 96 (7):528-32
    View PubMed
  158. Shuford CM, Comins DL, Whitten JL, Burnett JC, Muddiman DC. Improving limits of detection for B-type natriuretic peptide using PC-IDMS: an application of the ALiPHAT strategy. Analyst. 2010 Jan; 135(1):36-41. Epub 2009 Nov 19.
    View PubMed
  159. Frye RL, Simari RD, Gersh BJ, Burnett JC, Brumm S, Myerle K, Jaffe AS, Holmes DR, Lerman A, Terzic A. Ethical issues in cardiovascular research involving humans. Circulation. 2009 Nov 24; 120 (21):2113-21
    View PubMed
  160. Boerrigter G, Costello-Boerrigter LC, Burnett JC Jr. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin. 2009 Oct; 5 (4):501-14
    View PubMed
  161. McKie PM, Cataliotti A, Huntley BK, Martin FL, Olson TM, Burnett JC Jr. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol. 2009 Sep 8; 54 (11):1024-32
    View PubMed
  162. Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L, Ouyang J, Udelson JE, Gheorghiade M, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009 Sep; 30(18):2233-40. Epub 2009 Jun 27.
    View PubMed
  163. Chen HH, Martin FL, Gibbons RJ, Schirger JA, Wright RS, Schears RM, Redfield MM, Simari RD, Lerman A, Cataliotti A, Burnett JC Jr. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart. 2009 Aug; 95 (16):1315-9 Epub 2009 May 15
    View PubMed
  164. Miller WL, Burnett JC Jr, Hartman KA, Hodge DO, Giuliani I, Minard F, Larue C, Jaffe AS. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. Clin Chim Acta. 2009 Aug; 406(1-2):119-23. Epub 2009 Jun 11.
    View PubMed
  165. Kizer JR, Krauser DG, Rodeheffer RJ, Burnett JC Jr, Okin PM, Roman MJ, Umans JG, Best LG, Lee ET, Devereux RB. Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study). Am J Cardiol. 2009 Jul 15; 104(2):247-53. Epub 2009 Jun 03.
    View PubMed
  166. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A, Redfield MM, Potter LR, Burnett JC Jr, Simari RD. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A. 2009 Jul 7; 106 (27):11282-7 Epub 2009 June 18
    View PubMed
  167. Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr, Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghiade M, EVEREST Investigators. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J. 2009 Jul; 30(13):1666-73. Epub 2009 May 02.
    View PubMed
  168. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC Jr. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009 Jun; 49 (6):668-73 Epub 2009 Apr 24
    View PubMed
  169. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Huntley BK, Cataliotti A, Lapp H, Burnett JC Jr. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. Am J Physiol Regul Integr Comp Physiol. 2009 Jun; 296 (6):R1744-50 Epub 2009 Apr 22
    View PubMed
  170. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev. 2009 Jun; 14 (2):75-82 Epub 2008 Sept 03
    View PubMed
  171. Chen HH, Cataliotti A, Schirger JA, Martin FL, Harstad LK, Burnett JC Jr. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J Am Coll Cardiol. 2009 Apr 14; 53 (15):1302-8
    View PubMed
  172. Andrews GL, Shuford CM, Burnett JC, Hawkridge AM, Muddiman DC. Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. Journal of Chromatography B: Analytical Technologies in the Biomedical & Life Sciences. 2009 Apr 1; 877(10):948-54.
  173. Boerrigter G, Costello-Boerrigter LC, Abraham WT, St John Sutton MG, Heublein DM, Kruger KM, Hill MR, McCullough PA, Burnett JC Jr. Response to Cardiac Resynchronization Therapy Improves Renal Function. Importance of Forward and Backward Failure. J Card Fail. 2009 Feb 1; 15 (1):79-80
    View PubMed
  174. Lee CY, Lieu H, Burnett JC Jr. Designer natriuretic peptides. J Investig Med. 2009 Jan; 57 (1):18-21
    View PubMed
  175. Boerrigter G, Lapp H, Burnett JC. Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol. 2009; (191):485-506
    View PubMed
  176. Miller WL, Hartman KA, Grill DE, Burnett JC Jr, Jaffe AS. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem. 2009 Jan; 55 (1):78-84 Epub 2008 Nov 21
    View PubMed
  177. Martin FL, Chen HH, Cataliotti A, Burnett JC Jr. Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators. Rev Cardiovasc Med. 2008 Winter; 9(1):39-45.
    View PubMed
  178. Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M, EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008 Nov 11; 52(20):1640-8.
    View PubMed
  179. Cataliotti A, Chen HH, Schirger JA, Martin FL, Boerrigter G, Costello-Boerrigter LC, James KD, Polowy K, Miller MA, Malkar NB, Bailey KR, Burnett JC Jr. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation. 2008 Oct 21; 118 (17):1729-36 Epub 2008 Oct 06
    View PubMed
  180. Martin FL, Chen HH, Cataliotti A, Burnett JC Jr. B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin. 2008 Oct; 4 (4):449-54
    View PubMed
  181. Boerrigter G, Costello-Boerrigter LC, Abraham WT, Sutton MG, Heublein DM, Kruger KM, Hill MR, McCullough PA, Burnett JC Jr. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail. 2008 Sep; 14 (7):539-46 Epub 2008 May 27
    View PubMed
  182. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ, Ballew JD, de Andrade M, Burnett JC Jr, Olson TM. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med. 2008 Jul 10; 359(2):158-65.
    View PubMed
  183. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008 Jul 1; 52 (1):60-8
    View PubMed
  184. Friedewald VE Jr, Burnett JC Jr, Januzzi JL Jr, Roberts WC, Yancy CW. The editor's roundtable: B-type natriuretic peptide. Am J Cardiol. 2008 Jun 15; 101(12):1733-40. Epub 2008 Apr 22.
    View PubMed
  185. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008 Jun 11; 299(22):2656-66.
    View PubMed
  186. Korinek J, Boerrigter G, Mohammed SF, Burnett JC Jr. Insights into natriuretic peptides in heart failure: an update. Curr Heart Fail Rep. 2008 Jun; 5 (2):97-104
    View PubMed
  187. Mohammed SF, Korinek J, Chen HH, Burnett JC, Redfield MM. Nesiritide in acute decompensated heart failure: current status and future perspectives. Rev Cardiovasc Med. 2008 Summer; 9 (3):151-8
    View PubMed
  188. Owan TE, Chen HH, Frantz RP, Karon BL, Miller WL, Rodeheffer RJ, Hodge DO, Burnett JC Jr, Redfield MM. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail. 2008 May; 14 (4):267-75
    View PubMed
  189. Buchner S, Muscholl M, Debl K, Hense HW, Doring A, Stritzke J, Schunkert H, Jougasaki M, Burnett JC, Riegger GA, Luchner A. Left atrial size by planimetry is superior to M-mode diameter: biochemical calibration by atrial and brain natriuretic peptide. J Am Soc Echocardiogr. 2008 Apr; 21(4):380-5. Epub 2007 Jul 27.
    View PubMed
  190. Martinez-Rumayor A, Richards M, Burnett JC, Januzzi JL. Biology of the natriuretic peptides. Am J Cardiol. 2008 Feb 4; 101(3A Suppl S):3A-8A.
  191. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC Jr, Redfield MM. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008 Feb; 51 (2):289-95 Epub 2007 Dec 17
    View PubMed
  192. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. V2 receptor antagonism with tolvaptan in heart failure. Expert Opin Investig Drugs. 2007 Oct; 16 (10):1639-47
    View PubMed
  193. Martin FL, Supaporn T, Chen HH, Sandberg SM, Matsuda Y, Jougasaki M, Burnett JC Jr. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure. Am J Physiol Regul Integr Comp Physiol. 2007 Oct; 293 (4):R1580-5 Epub 2007 Aug 01
    View PubMed
  194. Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC Jr. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation. 2007 Sep 11; 116 (11 Suppl):I134-8
    View PubMed
  195. Costello-Boerrigter LC, Boerrigter G, Harty GJ, Cataliotti A, Redfield MM, Burnett JC Jr. Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Hypertension. 2007 Sep; 50: (3)481-8.
    View PubMed
  196. Frantz RP, Lowes BD, Grayburn PA, White M, Krause-Steinrauf H, Krishnan V, Uyeda L, Burnett JC, BEST Neurohumoral Substudy Investigators. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST). J Card Fail. 2007 Aug; 13 (6):437-44
    View PubMed
  197. Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, Jaffe AS. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007 Jul 17; 116 (3):249-57 Epub 2007 June 25
    View PubMed
  198. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007 Jun; 12 (2):131-42
    View PubMed
  199. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007 May; 49: (5)1128-33.
    View PubMed
  200. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007 May; 49: (5)1114-9.
    View PubMed
  201. Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS. Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clin Cardiol. 2007 May; 30 (5):245-50
    View PubMed
  202. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28; 297(12):1319-31.
    View PubMed
  203. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With, Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007 Mar 28; 297(12):1332-43.
    View PubMed
  204. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC Jr, Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007 Mar 27; 115 (12):1563-70 Epub 2007 Mar 12
    View PubMed
  205. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007 Mar 20; 49(11):1193-202. Epub 2007 Mar 06.
    View PubMed
  206. Boerrigter G, Burnett JC Jr. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev. 2007 Spring; 25: (1)30-45.
    View PubMed
  207. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007 Feb; 292 (2):R897-901 Epub 2006 Oct 26
    View PubMed
  208. Blair JEA, Manuchehry A, Chana A, Rossi J, Schrier RW, Burnett JC, Gheorghiade M. Prognostic markers in heart failure - Congestion, neurohormones, and the cardiorenal syndrome. Acute Cardiac Care. 2007; 9(4):207-13.
  209. Cataliotti A, Chen HH, James KD, Burnett JC Jr. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardiovasc Med. 2007 Jan; 17(1):10-4.
    View PubMed
  210. Ammar KA, Makwana R, Jacobsen SJ, Kors JA, Burnett JC Jr, Redfield MM, Yawn BP, Rodeheffer RJ. Impaired functional status and echocardiographic abnormalities signifying global dysfunction enhance the prognostic significance of previously unrecognized myocardial infarction detected by electrocardiography. Ann Noninvasive Electrocardiol. 2007 Jan; 12 (1):27-37
    View PubMed
  211. Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield MM, Matsuda Y, Burnett JC Jr. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol. 2006 Dec; 209: (3)943-9.
    View PubMed
  212. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: An essential target of evaluation and treatment. Am J Med. 2006 Dec; 119(12 Suppl 1):3-10.
  213. Burnett JC Jr. Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon. J Cardiol. 2006 Nov; 48 (5):235-41
    View PubMed
  214. Rule AD, Rodeheffer RJ, Larson TS, Burnett JC Jr, Cosio FG, Turner ST, Jacobsen SJ. Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc. 2006 Nov; 81(11):1427-34.
    View PubMed
  215. Chen HH, Schirger JA, Cataliotti A, Burnett JC Jr. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Heart Fail. 2006 Nov; 8(7):681-6. Epub 2006 Feb 03.
    View PubMed
  216. Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC Jr. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol. 2006 Oct; 17 (10):2742-7 Epub 2006 Aug 23
    View PubMed
  217. Belluardo P, Cataliotti A, Bonaiuto L, Giuffre E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC, Malatino LS. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006 Oct; 291(4):H1529-35. Epub 2006 Apr 28.
    View PubMed
  218. Chen HH, Burnett JC. Clinical application of the natriuretic peptides in heart failure. Eur Heart J Suppl. 2006 Sep; 8(E):E18-E25.
  219. Garbers DL, Chrisman TD, Wiegn P, Katafuchi T, Albanesi JP, Bielinski V, Barylko B, Redfield MM, Burnett JC. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab. 2006 Aug; 17(6):251-8. Epub 2006 Jun 30.
    View PubMed
  220. Chen HH, Burnett JC Jr. Therapeutic potential for existing and novel forms of natriuretic peptides. Heart Fail Clin. 2006 Jul; 2(3):365-73.
    View PubMed
  221. Cataliotti A, Chen HH, Redfield MM, Burnett JC Jr. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin. 2006 Jul; 2(3):269-76.
    View PubMed
  222. Bergeron S, Moller JE, Bailey KR, Chen HH, Burnett JC, Pellikka PA. Exertional changes in circulating cardiac natriuretic peptides in patients with suggested coronary artery disease. J Am Soc Echocardiogr. 2006 Jun; 19 (6):772-6
    View PubMed
  223. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006 May; 47 (5):874-80 Epub 2006 Apr 03
    View PubMed
  224. Detaint D, Messika-Zeitoun D, Chen HH, Rossi A, Avierinos JF, Scott C, Burnett JC Jr, Enriquez-Sarano M. Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. Am J Cardiol. 2006 Apr 1; 97 (7):1029-34 Epub 2006 Feb 28
    View PubMed
  225. Ammar KA, Makwana R, Redfield MM, Kors JA, Burnett JC Jr, Rodeheffer RJ. Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study. Am Heart J. 2006 Apr; 151: (4)799-805.
    View PubMed
  226. Werch CC, Grenard JL, Burnett J, Watkins JA, Ames S, Jobli E. Translation as a function of modality: the potential of brief interventions. Eval Health Prof. 2006 Mar; 29(1):89-125.
    View PubMed
  227. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006 Feb; 290 (2):F273-8 Epub 2005 Sept 27
    View PubMed
  228. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006 Jan 17; 47 (2):345-53 Epub 2006 Jan 04
    View PubMed
  229. Lisy O, Burnett JC Jr. New cardioprotective agent K201 is natriuretic and glomerular filtration rate enhancing. Circulation. 2006 Jan 17; 113 (2):246-51 Epub 2006 Jan 09
    View PubMed
  230. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005 Nov 29; 102 (48):17442-7 Epub 2005 Nov 17
    View PubMed
  231. Cataliotti A, Burnett JC Jr. Natriuretic peptides: novel therapeutic targets in heart failure. J Investig Med. 2005 Nov; 53: (7)378-84.
    View PubMed
  232. Miller WL, Burnett JC Jr, Hartman KA, Henle MP, Burritt MF, Jaffe AS. Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide. Am J Cardiol. 2005 Sep 15; 96(6):837-41.
    View PubMed
  233. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC Jr. Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation. 2005 Aug 9; 112(6):836-40. Epub 2005 Aug 01.
    View PubMed
  234. Patel JB, Valencik ML, Pritchett AM, Burnett JC Jr, McDonald JA, Redfield MM. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol. 2005 Aug; 289 (2):H777-84 Epub 2005 Mar 18
    View PubMed
  235. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc. 2005 Aug; 80 (8):1029-36
    View PubMed
  236. Detaint D, Messika-Zeitoun D, Avierinos JF, Scott C, Chen H, Burnett JC Jr, Enriquez-Sarano M. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation. 2005 May 10; 111 (18):2391-7
    View PubMed
  237. Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol. 2005 May; 288 (5):R1093-7 Epub 2004 Dec 30
    View PubMed
  238. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005 May; 11(4):260-9.
    View PubMed
  239. Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC Jr. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005 May; 67(5):1723-30.
    View PubMed
  240. Burnett JC. Nesiritide: new hope for acute heart failure syndromes? Eur Heart J Suppl. 2005 Apr; 7(B):B25-B30.
  241. Costello-Boerrigter LC, Burnett JC Jr. The prognostic value of N-terminal proB-type natriuretic peptide. Nat Clin Pract Cardiovasc Med. 2005 Apr; 2(4):194-201.
    View PubMed
  242. Burnett JC Jr. Natriuretic peptides and remodeling in heart failure. Heart Fail Clin. 2005 Apr; 1(1):129-39.
    View PubMed
  243. Munagala VK, Hart CY, Burnett JC Jr, Meyer DM, Redfield MM. Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure. Circulation. 2005 Mar 8; 111 (9):1128-35 Epub 2005 Feb 21
    View PubMed
  244. Miller WL, Hartman KA, Burritt MF, Borgeson DD, Burnett JC Jr, Jaffe AS. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem. 2005 Mar; 51 (3):569-77 Epub 2004 Dec 22
    View PubMed
  245. Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J. 2005 Mar; 149 (3):541-7
    View PubMed
  246. Dumoulin MJ, Adam A, Burnett J, Heublein D, Yamaguchi N, Lamontagne D. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides. Can J Physiol Pharmacol 2005 Feb; 83(2):166-73.
    View PubMed
  247. Lisy O, Redfield MM, Schirger JA, Burnett JC Jr. Atrial BNP endocrine function during chronic unloading of the normal canine heart. Am J Physiol Regul Integr Comp Physiol. 2005 Jan; 288 (1):R158-62
    View PubMed
  248. James KD, Cataliotti A, Schirger JA, Plonka S, Burnett JC Jr. Congestive heart failure: pharmacological agents and the potential of B-type natriuretic Peptide. Curr Med Chem. 2005; 12(12):1439-47.
    View PubMed
  249. Munagala VK, Burnett JC, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004 Dec; 29(12):707-69.
    View PubMed
  250. Jacobsen SJ, Mahoney DW, Redfield MM, Bailey KR, Burnett JC Jr, Rodeheffer RJ. Participation bias in a population-based echocardiography study. Ann Epidemiol. 2004 Sep; 14 (8):579-84
    View PubMed
  251. Boerrigter G, Burnett JC Jr. Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. Curr Heart Fail Rep. 2004 Sep; 1 (3):113-20
    View PubMed
  252. Khurana VG, Wijdicks EF, Heublein DM, McClelland RL, Meyer FB, Piepgras DG, Burnett JC Jr. A pilot study of dendroaspis natriuretic peptide in aneurysmal subarachnoid hemorrhage. Neurosurgery. 2004 Jul; 55 (1):69-75; discussion 75-6
    View PubMed
  253. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004 Jun 29; 109: (25)3176-81.
    View PubMed
  254. Pan S, Gulati R, Mueske CS, Witt TA, Lerman A, Burnett JC Jr, Simari RD. Gene transfer of a novel vasoactive natriuretic peptide stimulates cGMP and lowers blood pressure in mice. Am J Physiol Heart Circ Physiol. 2004 Jun; 286 (6):H2213-8 Epub 2004 Feb 12
    View PubMed
  255. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs. 2004 Jun; 13 (6):643-52
    View PubMed
  256. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC Jr. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004 Apr 6; 109(13):1680-5. Epub 2004 Mar 15.
    View PubMed
  257. Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett JC Jr. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004 Apr; 10 (2):115-9
    View PubMed
  258. Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, Burnett JC Jr. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation. 2004 Jan 20; 109: (2)249-54.
    View PubMed
  259. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev. 2004 Jan; 9 (1):53-61
    View PubMed
  260. Boerrigter G, Burnett JC. Endothelin in neurohormonal activation in heart failure. Coron Artery Dis. 2003 Nov; 14 (7):495-500
    View PubMed
  261. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol. 2003 May; 284(5):F1115-9.
    View PubMed
  262. Tsuruda T, Jougasaki M, Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lee SC, Salz-Gilman L, Nordstrom LJ, McGregor CG, Burnett JC. Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart. Regul Pept. 2003 Apr 15; 112 (1-3):161-6
    View PubMed
  263. Shapiro BP, Chen HH, Burnett JC Jr, Redfield MM. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc. 2003 Apr; 78 (4):481-6
    View PubMed
  264. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin North Am. 2003 Mar; 87 (2):475-91
    View PubMed
  265. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation. 2003 Feb 11; 107 (5):686-9
    View PubMed
  266. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003 Jan 8; 289 (2):194-202
    View PubMed
  267. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002 Dec 13; 91 (12):1127-34
    View PubMed
  268. Chen HH, Lainchbury JG, Burnett JC Jr. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol. 2002 Sep 18; 40 (6):1186-91
    View PubMed
  269. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002 Sep 4; 40 (5):976-82
    View PubMed
  270. Cataliotti A, Giordano M, De Pascale E, Giordano G, Castellino P, Jougasaki M, Costello LC, Boerrigter G, Tsuruda T, Belluardo P, Lee SC, Huntley B, Sandberg S, Malatino LS, Burnett JC Jr. CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. Am J Physiol Renal Physiol. 2002 Sep; 283(3):F464-72.
    View PubMed
  271. Best PJ, Burnett JC, Wilson SH, Holmes DR Jr, Lerman A. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res. 2002 Aug 1; 55 (2):375-84
    View PubMed
  272. Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M, Redfield MM, Burnett JC Jr. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail. 2002 Jun; 8 (3):149-54
    View PubMed
  273. Lainchbury JG, Lisy O, Burnett JC Jr, Meyer DM, Redfield MM. Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. Am J Physiol Regul Integr Comp Physiol. 2002 Apr; 282 (4):R993-8
    View PubMed
  274. Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation. 2002 Feb 26; 105 (8):999-1003
    View PubMed
  275. Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D'Assoro AB, Lee SC, Larsen AM, Cataliotti A, Burnett JC Jr. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res. 2002 Feb 8; 90 (2):128-34
    View PubMed
  276. Cataliotti A, Boerrigter G, Chen HH, Jougasaki M, Costello LC, Tsuruda T, Lee SC, Malatino LS, Burnett JC Jr. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation. 2002 Feb 5; 105 (5):639-44
    View PubMed
  277. Yusufi ANK, Cheng JF, Thompson MA, Burnett JC, Grande JP. Differential mechanisms of Ca2+ release from vascular smooth muscle cell microsomes. Experimental Biology & Medicine. 2002 Jan; 227(1):36-44.
  278. Miller WL, Bailey KR, Weston SA, Burnett JC Jr, Rodeheffer RJ. Hemodynamic and plasma atrial natriuretic peptide responses to acute digitalis therapy in patients with normal and impaired left ventricular function. Eur J Heart Fail. 2002 Jan; 4 (1):63-72
    View PubMed
  279. Yusufi AN, Cheng J, Thompson MA, Burnett JC, Grande JP. Differential mechanisms of Ca(2+) release from vascular smooth muscle cell microsomes. Exp Biol Med (Maywood). 2002 Jan; 227 (1):36-44
    View PubMed
  280. Frantz R, Olson L, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC. Effect of carvedilol on survival in severe chronic heart failure. Surv Anesthesiol. 2002; 46(4):227-8.
  281. Chen HH, Cataliotti A, Burnett JC Jr. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure. Curr Hypertens Rep. 2001 Dec; 3 Suppl 2:S15-21
    View PubMed
  282. Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, Bellanuova I, Tripepi R, Seminara G, Parlongo S, Stancanelli B, Bonanno G, Fatuzzo P, Rapisarda F, Belluardo P, Signorelli SS, Heublein DM, Lainchbury JG, Leskinen HK, Bailey KR, Redfield MM, Burnett JC Jr. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 2001 Nov; 76 (11):1111-9
    View PubMed
  283. Jougasaki M, Grantham JA, Redfield MM, Burnett JC Jr. Regulation of cardiac adrenomedullin in heart failure. Peptides. 2001 Nov; 22 (11):1841-50
    View PubMed
  284. Hart CY, Burnett JC Jr, Redfield MM. Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol. 2001 Nov; 281 (5):H1938-45
    View PubMed
  285. Corti R, Burnett JC, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001 Oct 9; 104(15):1856-62.
    View PubMed
  286. Chen HH, Lainchbury JG, Matsuda Y, Harty GJ, Burnett JC Jr. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension. 2001 Aug; 38 (2):187-91
    View PubMed
  287. Hart CY, Meyer DM, Tazelaar HD, Grande JP, Burnett JC Jr, Housmans PR, Redfield MM. Load versus humoral activation in the genesis of early hypertensive heart disease. Circulation. 2001 Jul 10; 104 (2):215-20
    View PubMed
  288. Hart CY, Hahn EL, Meyer DM, Burnett JC Jr, Redfield MM. Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs. Am J Physiol Heart Circ Physiol. 2001 Jul; 281 (1):H146-54
    View PubMed
  289. Lisy O, Lainchbury JG, Leskinen H, Burnett JC Jr. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001 Apr; 37 (4):1089-94
    View PubMed
  290. Honing ML, Smits P, Morrison PJ, Burnett JC Jr, Rabelink TJ. C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertension. 2001 Apr; 37(4):1179-83.
    View PubMed
  291. Jougasaki M, Heublein DM, Sandberg SM, Burnett JC Jr. Attenuated natriuretic response to adrenomedullin in experimental heart failure. J Card Fail. 2001 Mar; 7(1):75-83.
    View PubMed
  292. Nir A, Zhang DF, Fixler R, Burnett JC Jr, Eilam Y, Hasin Y. C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. Eur J Pharmacol. 2001 Feb 2; 412(3):195-201.
    View PubMed
  293. Wijdicks EF, Heublein DM, Burnett JC Jr. Increase and uncoupling of adrenomedullin from the natriuretic peptide system in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2001 Feb; 94(2):252-6.
    View PubMed
  294. Cases A, Haas J, Burnett JC, Romero JC. Hemodynamic and renal effects of acute and progressive nitric oxide synthesis inhibition in anesthetized dogs. Am J Physiol Regul Integr Comp Physiol. 2001 Jan; 280 (1):R143-8
    View PubMed
  295. d'Uscio LV, Quaschning T, Burnett JC, Luscher TF. Vasopeptidase Inhibition Prevents Endothelial Dysfunction of Resistance Arteries in Salt-Sensitive Hypertension in Comparison With Single ACE Inhibition. Hypertension. 2001 Jan; 37(1):28-33.
    View PubMed
  296. Luchner A, Borgeson DD, Grantham JA, Friedrich E, Riegger GA, Burnett JC Jr, Redfield MM. Relationship between left ventricular wall stress and ANP gene expression during the evolution of rapid ventricular pacing-induced heart failure in the dog. Eur J Heart Fail. 2000 Dec; 2(4):379-86.
    View PubMed
  297. Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett JC Jr. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol. 2000 Nov 1; 36 (5):1706-12
    View PubMed
  298. Burnett JC. Vasopeptidase inhibition. Curr Opin Nephrol Hypertens. 2000 Sep; 9 (5):465-8
    View PubMed
  299. Luchner A, Jougasaki M, Friedrich E, Borgeson DD, Stevens TL, Redfield MM, Riegger GA, Burnett JC Jr. Activation of cardiorenal and pulmonary tissue endothelin-1 in experimental heart failure. Am J Physiol Regul Integr Comp Physiol. 2000 Sep; 279(3):R974-9.
    View PubMed
  300. Lainchbury JG, Meyer DM, Jougasaki M, Burnett JC Jr, Redfield MM. Effects of adrenomedullin on load and myocardial performance in normal and heart-failure dogs. Am J Physiol Heart Circ Physiol. 2000 Sep; 279 (3):H1000-6
    View PubMed
  301. Yamamoto K, Burnett JC Jr, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 2000 Sep; 6 (3):194-200
    View PubMed
  302. Harker-Murray AK, Tajik AJ, Ishikura F, Meyer D, Burnett JC, Redfield MM. The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. J Card Fail. 2000 Sep; 6(3):233-42.
    View PubMed
  303. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, Riegger GA, Schunkert H. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000 Aug; 18(8):1121-8.
    View PubMed
  304. Lisy O, Redfield MM, Jovanovic S, Jougasaki M, Jovanovic A, Leskinen H, Terzic A, Burnett JC Jr. Mechanical unloading versus neurohumoral stimulation on myocardial structure and endocrine function In vivo. Circulation. 2000 Jul 18; 102 (3):338-43
    View PubMed
  305. Dzeja PP, Redfield MM, Burnett JC, Terzic A. Failing energetics in failing hearts. Curr Cardiol Rep. 2000 May; 2 (3):212-7
    View PubMed
  306. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000 May; 2 (3):198-205
    View PubMed
  307. Grantham JA, Schirger JA, Wennberg PW, Sandberg S, Heublein DM, Subkowski T, Burnett JC Jr. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis. Circulation. 2000 Apr 25; 101 (16):1976-81
    View PubMed
  308. Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000 Apr; 35 (5):1256-62
    View PubMed
  309. Collins E, Bracamonte MP, Burnett JC Jr, Miller VM. Mechanism of relaxations to dendroaspis natriuretic peptide in canine coronary arteries. J Cardiovasc Pharmacol. 2000 Apr; 35 (4):614-8
    View PubMed
  310. Burnett JC Jr. Biomedical research at Mayo Clinic: a tradition of collaboration and a vision for year 2000 and beyond. Mayo Clin Proc. 2000 Apr; 75(4):337-9.
    View PubMed
  311. Jougasaki M, Burnett JC Jr. Adrenomedullin as a renal regulator peptide. Nephrol Dial Transplant. 2000 Mar; 15 (3):293-5
    View PubMed
  312. Chen HH, Oh KY, Terzic A, Burnett JC Jr. The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure. Eur J Heart Fail. 2000 Mar; 2 (1):33-40
    View PubMed
  313. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Miller V, Simari RD, Burnett JC Jr. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol. 2000 Mar 1; 35 (3):796-801
    View PubMed
  314. Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfield MM, Burnett JC Jr. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation. 2000 Jan 4-11; 101 (1):14-7
    View PubMed
  315. Lainchbury JG, Burnett JC Jr, Meyer D, Redfield MM. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol. 2000 Jan; 278 (1):H33-40
    View PubMed
  316. Frantz RP, Heublein DM, Lunn RJ, Buck CF, Burnett JC. Hemodynamic and neurohumoral effects of inhaled nitric oxide and intravenous sodium nitroprusside in cardiac transplant candidates with pulmonary hypertension. American Heart Journal. 2000.
  317. Wei C, Burnett JC Jr. Inhibition by calcium antagonism of circulating and renal endothelin in experimental congestive heart failure. Am J Physiol Heart Circ Physiol. 2000 Jan; 278(1):H263-8.
  318. Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 2000; 66 (10):855-72
    View PubMed
  319. Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999 Dec 14; 100 (24):2443-8
    View PubMed
  320. O'Connor CM, Gattis WA, Gheorghiade M, Granger CB, Gilbert J, McKenney JM, Messineo FC, Burnett JC, Katz SD, Elkayam U, Kasper EK, Goldstein S, Cody RJ, Massie BM. A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J. 1999 Dec; 138(6 Pt 1):1140-8.
    View PubMed
  321. Black HR, Kuller LH, O'Rourke MF, Weber MA, Alderman MH, Benetos A, Burnett J, Cohn JN, Franklin SS, Mancia G, Safar M, Zanchetti A. The first report of the Systolic and Pulse Pressure (SYPP) Working Group. J Hypertens. 1999 Dec; 17(Suppl 5):S3-14.
  322. Dzeja PP, Pucar D, Redfield MM, Burnett JC, Terzic A. Reduced activity of enzymes coupling ATP-generating with ATP-consuming processes in the failing myocardium. Mol Cell Biochem. 1999 Nov; 201 (1-2):33-40
    View PubMed
  323. Kottke TE, Roger VL, Nguyen TT, Dale LC, Burnett JC, Tajik AJ. CardioVision 2020: a multidisciplinary cardiovascular disease prevention project. European Heart Journal Supplement. 1999 Nov; 1(S):S14-S18.
  324. Wennberg PW, Miller VM, Rabelink T, Burnett JC Jr. Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. Am J Physiol. 1999 Oct; 277 (4):H1618-21
    View PubMed
  325. Bracamonte MP, Burnett JC Jr, Miller VM. Activation of soluble guanylate cyclase and potassium channels contribute to relaxations to nitric oxide in smooth muscle derived from canine femoral veins. J Cardiovasc Pharmacol. 1999 Sep; 34 (3):407-13
    View PubMed
  326. Lisy O, Burnett JC Jr. Potential future therapies: natriuretic peptides. Coron Artery Dis. 1999 Sep; 10 (6):389-94
    View PubMed
  327. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999 Sep-Oct; 111 (5):406-16
    View PubMed
  328. Lisy O, Jougasaki M, Heublein DM, Schirger JA, Chen HH, Wennberg PW, Burnett JC. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int. 1999 Aug; 56 (2):502-8
    View PubMed
  329. Dzeja PP, Vitkevicius KT, Redfield MM, Burnett JC, Terzic A. Adenylate kinase-catalyzed phosphotransfer in the myocardium : increased contribution in heart failure. Circ Res. 1999 May 28; 84 (10):1137-43
    View PubMed
  330. Jovanovic S, Grantham AJ, Tarara JE, Burnett JC Jr, Jovanovic A, Terzic A. Increased number of cardiomyocytes in cross-sections from tachycardia-induced cardiomyopathic hearts. Int J Mol Med. 1999 Feb; 3 (2):153-5
    View PubMed
  331. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, Burnett JC Jr. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc. 1999 Feb; 74 (2):126-30
    View PubMed
  332. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999 Feb; 17(1):S37-43.
    View PubMed
  333. Hasdai D, Holmes DR Jr, Higano ST, Burnett JC Jr, Lerman A. Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc. 1998 Dec; 73: (12)1133-40.
    View PubMed
  334. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 1998 Dec; 32(7):1839-44.
    View PubMed
  335. Jougasaki M, Schirger JA, Simari RD, Burnett JC Jr. Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. Hypertension. 1998 Nov; 32 (5):917-22
    View PubMed
  336. Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC Jr. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol. 1998 Sep; 275 (3):F410-4
    View PubMed
  337. Borgeson DD, Stevens TL, Heublein DM, Matsuda Y, Burnett JC. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. Clin Sci (Lond). 1998 Aug; 95(2):195-202.
    View PubMed
  338. Barber DA, Burnett JC Jr, Fitzpatrick LA, Sieck GC, Miller VM. Gender and relaxation to C-type natriuretic peptide in porcine coronary arteries. J Cardiovasc Pharmacol. 1998 Jul; 32 (1):5-11
    View PubMed
  339. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr, Holmes DR Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998 Jun 2; 97 (21):2123-8
    View PubMed
  340. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett JC Jr. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol. 1998 May; 274 (5):H1684-9
    View PubMed
  341. Borgeson DD, Grantham JA, Williamson EE, Luchner A, Redfield MM, Opgenorth TJ, Burnett JC Jr. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension. 1998 Mar; 31 (3):766-70
    View PubMed
  342. Grantham JA, Schirger JA, Williamson EE, Heublein DM, Wennberg PW, Kirchengast M, Muenter K, Subkowski T, Burnett JC Jr. Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis. J Cardiovasc Pharmacol. 1998; 31 Suppl 1:S22-6
    View PubMed
  343. Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol. 1998; 32 Suppl 3:S22-8
    View PubMed
  344. Rasmussen TE, Jougasaki M, Supaporn T, Hallett JW Jr, Brooks DP, Burnett JC Jr. Cardiovascular actions of ET-B activation in vivo and modulation by receptor antagonism. Am J Physiol. 1998 Jan; 274 (1):R131-8
    View PubMed
  345. Honing MLH, Vuong TD, Morrison PJ, van Heunben-Nolsen D, Joles JA, Burnett JC Jr, Rabelink TJ. Vasodilator actions of bradykinin are partially mediated through release of c-type natruiretic peptide. JASN. 1998; 9:A1723.
  346. Yamamoto K, Burnett JC Jr, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997 Nov; 273 (5):H2406-14
    View PubMed
  347. Barber DA, Park YS, Burnett JC Jr, Miller VM. Adrenomedullin-mediated relaxations in veins are endothelium-dependent and distinct from arteries. J Cardiovasc Pharmacol. 1997 Nov; 30 (5):695-701
    View PubMed
  348. Chini EN, Chini CC, Bolliger C, Jougasaki M, Grande JP, Burnett JC Jr, Dousa TP. Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. Kidney Int. 1997 Oct; 52 (4):917-25
    View PubMed
  349. Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfield MM, Burnett JC Jr. Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Physiol. 1997 Oct; 273 (4):R1392-9
    View PubMed
  350. Zhu WX, Johnson SB, Brandt R, Burnett J, Burnett J, Packer DL. Impact of volume loading and load reduction on ventricular refractoriness and conduction properties in canine congestive heart failure. J Am Coll Cardiol. 1997 Sep; 30 (3):825-33
    View PubMed
  351. Chau WL, Burnett JC Jr. Treatment of congestive heart failure in the elderly: emphasis on renal functional changes and impact of therapy. Coron Artery Dis. 1997 Aug-Sep; 8(8-9):505-9.
    View PubMed
  352. Brandt RR, Mattingly MT, Clavell AL, Barclay PL, Burnett JC Jr. Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo. Hypertension. 1997 Aug; 30 (2 Pt 1):184-90
    View PubMed
  353. Wei CM, Clavell AL, Burnett JC. Atrial and pulmonary endothelin mRNA is increased in a canine model of chronic low cardiac output. Am J Physiol Regul Integr Comp Physiol. 1997 Aug; 273(2):R 838-R 844.
  354. Wijdicks EF, Schievink WI, Burnett JC Jr. Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1997 Aug; 87(2):275-80.
    View PubMed
  355. Rust OA, Bofill JA, Zappe DH, Hall JE, Burnett JC Jr, Martin JN Jr. The origin of endothelin-1 in patients with severe preeclampsia. Obstetrics & Gynecology. 1997 May; 89(5 Pt 1):754-7.
    View PubMed
  356. Grantham JA, Borgeson DD, Burnett JC Jr. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol. 1997 Apr; 272 (4 Pt 2):R1077-83
    View PubMed
  357. Jougasaki M, Aarhus LL, Heublein DM, Sandberg SM, Burnett JC Jr. Role of prostaglandins and renal nerves in the renal actions of adrenomedullin. Am J Physiol. 1997 Feb; 272 (2 Pt 2):F260-6
    View PubMed
  358. Yamamoto K, Nishimura RA, Burnett JC Jr, Redfield MM. Assessment of left ventricular end-diastolic pressure by Doppler echocardiography: contribution of duration of pulmonary venous versus mitral flow velocity curves at atrial contraction. J Am Soc Echocardiogr. 1997 Jan-Feb; 10 (1):52-9
    View PubMed
  359. Burnett JC Jr. Coronary endothelial dysfunction in the hypertensive patient: from myocardial ischemia to heart failure. J Hum Hypertens. 1997 Jan; 11 (1):45-9
    View PubMed
  360. Burnett JC Jr. Coronary endothelial function in health and disease. Drugs. 1997; 53 Suppl 1:20-9
    View PubMed
  361. Yamamoto K, Burnett JC Jr, Meyer LM, Sinclair L, Stevens TL, Redfield MM. Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model. Am J Physiol. 1996 Dec; 271 (6 Pt 2):R1529-34
    View PubMed
  362. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996 Dec; 28 (6):988-94
    View PubMed
  363. Supaporn T, Sandberg SM, Borgeson DD, Heublein DM, Luchner A, Wei CM, Dousa TP, Burnett JC Jr. Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. 1996 Nov; 50 (5):1718-25
    View PubMed
  364. Banks M, Wei CM, Kim CH, Burnett JC Jr, Miller VM. Mechanism of relaxations to C-type natriuretic peptide in veins. Am J Physiol. 1996 Nov; 271 (5 Pt 2):H1907-11
    View PubMed
  365. Wright RS, Wei CM, Kim CH, Kinoshita M, Matsuda Y, Aarhus LL, Burnett JC Jr, Miller WL. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. J Am Coll Cardiol. 1996 Oct; 28 (4):1031-8
    View PubMed
  366. Luchner A, Stevens TL, Borgeson DD, Redfield MM, Bailey JE, Sandberg SM, Heublein DM, Burnett JC Jr. Angiotensin II in the evolution of experimental heart failure. Hypertension. 1996 Sep; 28 (3):472-7
    View PubMed
  367. Stevens TL, Rasmussen TE, Wei CM, Kinoshita M, Matsuda Y, Burnett JC Jr. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Card Fail. 1996 Jun; 2 (2):119-25
    View PubMed
  368. Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei CM, McKinley LJ, Burnett JC Jr. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest. 1996 May 15; 97 (10):2370-6
    View PubMed
  369. Supaporn T, Wennberg PW, Wei CM, Kinoshita M, Matsuda Y, Burnett JC. Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin Sci (Lond). 1996 May; 90 (5):357-62
    View PubMed
  370. Nir A, Rein AJ, Burnett JC, Driscoll DJ. [Management of heart failure in infants and children and infants in the 90s]. Harefuah. 1996 May 1; 130(9):626-9.
    View PubMed
  371. Clavell AL, Mattingly MT, Stevens TL, Nir A, Wright S, Aarhus LL, Heublein DM, Burnett JC Jr. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest. 1996 Mar 1; 97 (5):1286-92
    View PubMed
  372. Cannan CR, Burnett JC Jr, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation. 1996 Feb 15; 93 (4):646-51
    View PubMed
  373. Wei CM, Miller VM, Schaff HV, Burnett JC Jr. Specificity of C-type and atrial natriuretic peptides in human blood vessels. Endothelium. 1996; 4(1):23-8.
  374. Goerss JB, Michels VV, Burnett J, Burnett J, Driscoll DJ, Miller F, Rodeheffer R, Miller F, Rodeheffer R, Tajik AJ, Schaid D, Schaid D. Frequency of familial dilated cardiomyopathy. Eur Heart J. 1995 Dec; 16 Suppl O:2-4
    View PubMed
  375. Cannan CR, Burnett JC Jr, Brandt RR, Lerman A. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation. 1995 Dec 1; 92 (11):3312-7
    View PubMed
  376. Lerman A, Holmes DR Jr, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 1995 Nov 1; 92 (9):2426-31
    View PubMed
  377. Chini EN, Choi E, Grande JP, Burnett JC, Dousa TP. Adrenomedullin suppresses mitogenesis in rat mesangial cells via cAMP pathway. Biochem Biophys Res Commun. 1995 Oct 24; 215(3):868-73.
    View PubMed
  378. Flickinger AL, Burnett JC Jr, Turner ST. Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc. 1995 Oct; 70 (10):932-8
    View PubMed
  379. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995 Aug 1; 92 (3):286-9
    View PubMed
  380. Brandt RR, Heublein DM, Aarhus LL, Lewicki JA, Burnett JC Jr. Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide. Am J Physiol. 1995 Jul; 269 (1 Pt 2):H326-31
    View PubMed
  381. Evans MA, Burnett JC Jr, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol. 1995 May; 25(6):1445-50.
    View PubMed
  382. Textor SC, Burnett JC Jr, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, Porayko M, Wiesner R, Krom R, Gores G, Krom R, Gores G, Hay E, Hay E. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 1995 May; 47 (5):1426-33
    View PubMed
  383. Margulies KB, Barclay PL, Burnett JC Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation. 1995 Apr 1; 91(7):2036-42.
    View PubMed
  384. Jougasaki M, Wei CM, Aarhus LL, Heublein DM, Sandberg SM, Burnett JC Jr. Renal localization and actions of adrenomedullin: a natriuretic peptide. Am J Physiol. 1995 Apr; 268 (4 Pt 2):F657-63
    View PubMed
  385. Stevens TL, Burnett JC Jr, Kinoshita M, Matsuda Y, Redfield MM. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest. 1995 Mar; 95 (3):1101-8
    View PubMed
  386. Clavell AL, Stingo AJ, Margulies KB, Brandt RR, Burnett JC Jr. Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol. 1995 Mar; 268 (3 Pt 2):F455-60
    View PubMed
  387. Brandt RR, Heublein DM, Mattingly MT, Pittelkow MR, Burnett JC Jr. Presence and secretion of atrial natriuretic peptide from cultured human aortic endothelial cells. Am J Physiol. 1995 Feb; 268 (2 Pt 2):H921-5
    View PubMed
  388. Jougasaki M, Wei CM, Heublein DM, Sandberg SM, Burnett JC Jr. Immunohistochemical localization of adrenomedullin in canine heart and aorta. Peptides. 1995; 16 (4):773-5
    View PubMed
  389. Mattingly MT, Burnett JC Jr. Angiotensin II aws a modulator of renal function in cardiovascular disease. CHOICES IN CARDIOLOGY. 1995; 9(1):10-3.
  390. Mattingly MT, Burnett JC Jr. Angiotensin II as a modulator of renal function in cardiovascular disease. Choices In Cardiology. 1995; 9(1):10-3.
  391. Nir A, Beers KW, Clavell AL, Wei CM, Heublein DM, Dousa TP, Burnett JC Jr. CNP is present in canine renal tubular cells and secreted by cultured opossum kidney cells. Am J Physiol. 1994 Dec; 267 (6 Pt 2):R1653-7
    View PubMed
  392. Wei CM, Hu S, Miller VM, Burnett JC Jr. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun. 1994 Nov 30; 205 (1):765-71
    View PubMed
  393. Textor SC, Schwartz L, Canzanello VJ, Wiesner R, Taler SJ, Porayko M, Wilson DJ, Krom R, Burnett JC, Romero JC. Resolution of posttransplant hypertension after liver transplantation despite impaired glomerular filtration. J Am Soc Nephrol. 1994 Nov; 5 (5):1223-30
    View PubMed
  394. Margulies KB, Burnett JC Jr. Inhibition of cyclic GMP phosphodiesterases augments renal responses to atrial natriuretic factor in congestive heart failure. J Card Fail. 1994 Oct; 1(1):71-80.
    View PubMed
  395. Mattingly MT, Brandt RR, Heublein DM, Wei CM, Nir A, Burnett JC Jr. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int. 1994 Sep; 46 (3):744-7
    View PubMed
  396. Chan DP, Clavell A, Keiser J, Burnett JC Jr. Effects of renin-angiotensin system in mediating endothelin-induced renal vasoconstriction: therapeutic implications. J Hypertens Suppl. 1994 Jul; 12(4):S43-9.
    View PubMed
  397. Wei CM, Kim CH, Khraibi AA, Miller VM, Burnett JC Jr. Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro. Hypertension. 1994 Jun; 23 (6 Pt 2):903-7
    View PubMed
  398. Stevens TL, Wei CM, Aahrus LL, Heublein DM, Kinoshita M, Matsuda Y, Burnett JC Jr. Modulation of exogenous and endogenous atrial natriuretic peptide by a receptor inhibitor. Hypertension. 1994 May; 23 (5):613-8
    View PubMed
  399. Nir A, Clavell AL, Heublein D, Aarhus LL, Burnett JC Jr. Acute hypoxia and endogenous renal endothelin. J Am Soc Nephrol. 1994 May; 4 (11):1920-4
    View PubMed
  400. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Wright S, Kao PC, Edwards WD, Burnett JC Jr. Endothelin in human congestive heart failure. Circulation. 1994 Apr; 89 (4):1580-6
    View PubMed
  401. Brandt RR, Redfield MM, Aarhus LL, Lewicki JA, Burnett JC Jr. Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure. Am J Physiol. 1994 Mar; 266 (3 Pt 2):R936-43
    View PubMed
  402. O'Murchu B, Miller VM, Perrella MA, Burnett JC Jr. Increased production of nitric oxide in coronary arteries during congestive heart failure. J Clin Invest. 1994 Jan; 93 (1):165-71
    View PubMed
  403. Schersten H, Aarnio P, Burnett JC Jr, McGregor CG, Miller VM. Endothelin-1 in bronchoalveolar lavage during rejection of allotransplanted lungs. Transplantation. 1994 Jan; 57 (1):159-61
    View PubMed
  404. Clavell AL, Burnett JC Jr. Physiologic and pathophysiologic roles of endothelin in the kidney. Curr Opin Nephrol Hypertens. 1994 Jan; 3 (1):66-72
    View PubMed
  405. Lerman A, Burnett JC Jr. Endothelium in early atherosclerosis. Cardiovascular Risk Factors. 1994; 4:92-96.
  406. Michels VV, Moll PP, Rodeheffer RJ, Miller FA Jr, Tajik AJ, Burnett JC Jr, Driscoll DJ, Thibodeau SN, Ansari AA, Herskowitz A. Circulating heart autoantibodies in familial as compared with nonfamilial idiopathic dilated cardiomyopathy. Mayo Clin Proc. 1994 Jan; 69 (1):24-7
    View PubMed
  407. Nir A, Beers KW, Clavell AL, Weis CM, Hueblein DH, Dousa TP, Burnett JC Jr. C-type natriuretic peptide is present in canine renal tubular cells and secreted by cultured opossum kidney cells. Amer J Integrative 3(6)R1653-R1657. 1994; Physiol: Regulatory and.
  408. Wei C-M, Burnett JC Jr. Discovery of vasonatrin peptide. Drug News & Perspectives. 1994; 7(9):531-4.
  409. Lerman A, Webster MW, Chesebro JH, Edwards WD, Wei CM, Fuster V, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993 Dec; 88 (6):2923-8
    View PubMed
  410. Clavell AL, Stingo AJ, Aarhus LL, Burnett JC Jr. Biological actions of brain natriuretic peptide in thoracic inferior vena caval constriction. Am J Physiol. 1993 Dec; 265 (6 Pt 2):R1416-22
    View PubMed
  411. Michels VV, Pastores GM, Moll PP, Driscoll DJ, Miller FA, Burnett JC, Rodeheffer RJ, Tajik JA, Beggs AH, Kunkel LM. Dystrophin analysis in idiopathic dilated cardiomyopathy. J Med Genet. 1993 Nov; 30 (11):955-7
    View PubMed
  412. Wei CM, Kim CH, Miller VM, Burnett JC Jr. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest. 1993 Oct; 92 (4):2048-52
    View PubMed
  413. Brandt RR, Wright RS, Redfield MM, Burnett JC Jr. Atrial natriuretic peptide in heart failure. J Am Coll Cardiol. 1993 Oct; 22 (4 Suppl A):86A-92A
    View PubMed
  414. Pitt B, Burnett JC Jr, Packer M, Schwartz K, Smith TW, Sole MJ, Wilson JR. Mechanisms and management of heart failure--implications of clinical trials for clinical practice--proceedings of a symposium sponsored by the national heart, lung and blood institute. 2. New insights into the epidemiology and pathophysiology of heart failure- discussion IV. J Am Coll Cardiol. 1993 Oct; 22(4 Suppl A):A106.
  415. Pitt B, Burnett JC Jr, Katz AM, Leier CV, Packer M, Poolewilson PA, Schwartz K, Sole MJ, Vatner SF. Mechanisms and management of heart failure--implications of clinical trials for clinical practice-- proceedings of a symposium sponsored by the national heart, lung, and blood institute. 2. New insights into the epidemiology and pathophysiology of heart failure-- discussion II. J Am Coll Cardiol. 1993 Oct; 22(4 Suppl A):A41-A42.
  416. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, Edwards WD, Schaff HV, Burnett JC Jr. Natriuretic peptide system in human heart failure. Circulation. 1993 Sep; 88 (3):1004-9
    View PubMed
  417. Wei CM, Kao PC, Lin JT, Heublein DM, Schaff HV, Burnett JC Jr. Circulating beta-atrial natriuretic factor in congestive heart failure in humans. Circulation. 1993 Sep; 88 (3):1016-20
    View PubMed
  418. Rodeheffer RJ, Naruse M, Atkinson JB, Naruse K, Burnett JC Jr, Merrill WH, Frist WH, Demura H, Inagami T. Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation. 1993 Aug; 88 (2):364-71
    View PubMed
  419. Fett DL, Cavero PG, Burnett JC Jr. Low-dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure. J Am Soc Nephrol. 1993 Aug; 4 (2):162-7
    View PubMed
  420. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Biological role for the endothelin-A receptor in aortic cross-clamping. Hypertension. 1993 Jul; 22 (1):62-6
    View PubMed
  421. Perrella MA, Aarhus LL, Heublein DM, Lewicki JA, Burnett JC Jr. Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure. Am J Physiol. 1993 Jul; 265 (1 Pt 2):H401-8
    View PubMed
  422. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993 Jul; 73(1):205-9.
    View PubMed
  423. Redfield MM, Aarhus LL, Wright RS, Burnett JC Jr. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation. 1993 Jun; 87 (6):2016-22
    View PubMed
  424. Textor SC, Wiesner R, Wilson DJ, Wiesner R, Porayko M, Romero JC, Burnett JC Jr, Gores G, Hay E, Gores G, Hay E, Dickson ER, Krom RA. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993 Jun; 55 (6):1332-9
    View PubMed
  425. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993 May 1; 341 (8853):1105-9
    View PubMed
  426. Clavell A, Stingo A, Margulies K, Lerman A, Underwood D, Burnett JC Jr. Physiological significance of endothelin. Circulation. 1993 May; 87(Suppl 5):V-45-V-50.
  427. Clavell AL, Stingo AJ, Wei CM, Heublein DM, Burnett JC Jr. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol. 1993 Feb; 264 (2 Pt 2):R290-5
    View PubMed
  428. Miller WL, Cavero PG, Aarhus LL, Heublein DM, Burnett JC Jr. Endothelin-mediated cardiorenal hemodynamic and neuroendocrine effects are attenuated by nitroglycerin in vivo. Am J Hypertens. 1993 Feb; 6 (2):156-63
    View PubMed
  429. Khraibi AA, Heublein DM, Knox FG, Burnett JC Jr. Increased plasma level of endothelin-1 in the Okamoto spontaneously hypertensive rat. Mayo Clin Proc. 1993 Jan; 68 (1):42-6
    View PubMed
  430. Margulies KB, Burnett JC Jr. Neutral endopeptidase 24.11: a modulator of natriuretic peptides. Semin Nephrol. 1993 Jan; 13(1):71-7.
    View PubMed
  431. Michels VV, Tazelaar HD, Driscoll DJ, Burnett JC Jr, Miller FA Jr, Tajik AJ, Rodeheffer RJ, Moll PP. Histopathology of familial versus nonfamilial dilated cardiomyopathy. Cardiovasc Pathol. 1993; 2:219-223.
  432. Wei CM, Aarhus LL, Miller VM, Burnett JC Jr. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol. 1993 Jan; 264 (1 Pt 2):H71-3
    View PubMed
  433. Clavell AL, Stingo AJ, Margulies KB, Lerman A, Underwood D, Burnett JC. The physiologic significance of endothelin: its role in congestive heart failure. Circulation. 1993; 87 (suppl V):V45-50.
  434. Miller WL, Burnett JC Jr. Circulating paracrine, autocrine mechanisms in heart failure. Curr Opin Cardiol. 1993; 8(3).
  435. Lerman A, Burnett JC Jr. Intact and altered endothelium in regulation of vasomotion. Circulation. 1992 Dec; 86(6 Suppl):III12-19.
    View PubMed
  436. Khraibi AA, Granger JP, Haas JA, Burnett JC Jr, Knox FG. Intrarenal pressures during direct inhibition of sodium transport. Am J Physiol. 1992 Dec; 263 (6 Pt 2):R1182-6
    View PubMed
  437. Stingo AJ, Clavell AL, Heublein DM, Wei CM, Pittelkow MR, Burnett JC Jr. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol. 1992 Oct; 263 (4 Pt 2):H1318-21
    View PubMed
  438. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol. 1992 Oct; 20 (4):849-53
    View PubMed
  439. Heublein DM, Clavell AL, Stingo AJ, Lerman A, Wold L, Burnett JC Jr. C-type natriuretic peptide immunoreactivity in human breast vascular endothelial cells. Peptides. 1992 Sep-Oct; 13 (5):1017-9
    View PubMed
  440. Underwood RD, Aarhus LL, Heublein DM, Burnett JC Jr. Endothelin in thoracic inferior vena caval constriction model of heart failure. Am J Physiol. 1992 Sep; 263 (3 Pt 2):H951-5
    View PubMed
  441. Sandok EK, Lerman A, Stingo AJ, Perrella MA, Gloviczki P, Burnett JC Jr. Endothelin in a model of acute ischemic renal dysfunction: modulating action of atrial natriuretic factor. J Am Soc Nephrol. 1992 Aug; 3 (2):196-202
    View PubMed
  442. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992 Aug; 67 (8):719-24
    View PubMed
  443. Textor SC, Wilson DJ, Lerman A, Romero JC, Burnett JC Jr, Wiesner R, Wiesner R, Dickson ER, Krom RA. Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation. Transplantation. 1992 Jul; 54 (1):74-80
    View PubMed
  444. Miller VM, Burnett JC Jr. Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. Am J Physiol. 1992 Jul; 263 (1 Pt 2):H103-8
    View PubMed
  445. Perrella MA, Edell ES, Krowka MJ, Cortese DA, Burnett JC Jr. Endothelium-derived relaxing factor in pulmonary and renal circulations during hypoxia. Am J Physiol. 1992 Jul; 263 (1 Pt 2):R45-50
    View PubMed
  446. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992 Jul; 20(1):3-16.
    View PubMed
  447. Chan DP, Sandok EK, Aarhus LL, Heublein DM, Burnett JC Jr. Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog. Am J Hypertens. 1992 Jun; 5 (6 Pt 1):354-60
    View PubMed
  448. Lerman A, Sandok EK, Hildebrand FL Jr, Burnett JC Jr. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation. 1992 May; 85 (5):1894-8
    View PubMed
  449. Perrella MA, Schwab TR, O'Murchu B, Redfield MM, Wei CM, Edwards BS, Burnett JC Jr. Cardiac atrial natriuretic factor during evolution of congestive heart failure. Am J Physiol. 1992 Apr; 262 (4 Pt 2):H1248-55
    View PubMed
  450. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, Burnett JC, Rodeheffer RJ, Chesebro JH, Tazelaar HD. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992 Jan 9; 326(2):77-82.
    View PubMed
  451. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol. 1992 Jan; 262 (1 Pt 2):H308-12
    View PubMed
  452. Margulies K, Schirger J, Burnett J Jr. Radiocontrast-induced nephropathy: current status and future prospects. Int Angiol. 1992 Jan-Mar; 11(1):20-5.
    View PubMed
  453. Gutkowska J, Tremblay J, Bolterman R, Olsen M, Burnett J, Romero C, Fass D. Cellular responses in canine renal medulla J Hypertens. 1992; 10:S112.
  454. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Immunoreacttivita dell'endotelina circolante e tissutale nell'aterosclerosi avanzata. Focus on endothelium and vascular diseases 2 (. 1992; 2): 44-7.
  455. Silberbach M, Stejskal E, Foker J, Bianco R, Tobian L, Burnett JC Jr, Einzig S. Newborn cardiorenal dynamics: a state of atrial natriuretic peptide unresponsiveness. Am J Physiol. 1991 Dec; 261(6 Pt 2):H2069-74.
    View PubMed
  456. Margulies KB, Perrella MA, McKinley LJ, Burnett JC Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest. 1991 Nov; 88 (5):1636-42
    View PubMed
  457. Margulies KB, Hildebrand FL, Heublein DM, Burnett JC Jr. Radiocontrast increases plasma and urinary endothelin. J Am Soc Nephrol. 1991 Nov; 2 (5):1041-5
    View PubMed
  458. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991 Oct 3; 325(14):997-1001.
    View PubMed
  459. Torres VE, Wilson DM, Burnett JC Jr, Johnson CM, Offord KP. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc. 1991 Oct; 66 (10):1010-7
    View PubMed
  460. Perrella MA, Margulies KB, Burnett JC Jr. Pathophysiology of congestive heart failure: role of atrial natriuretic factor and therapeutic implications. Can J Physiol Pharmacol. 1991 Oct; 69 (10):1576-81
    View PubMed
  461. Abassi Z, Burnett JC Jr, Grushka E, Hoffman A, Haramati A, Winaver J. Atrial natriuretic peptide and renal cGMP in rats with experimental heart failure. Am J Physiol. 1991 Oct; 261(4 Pt 2):R858-64.
    View PubMed
  462. Perrella MA, Hildebrand FL Jr, Margulies KB, Burnett JC Jr. Endothelium-derived relaxing factor in regulation of basal cardiopulmonary and renal function. Am J Physiol. 1991 Aug; 261 (2 Pt 2):R323-8
    View PubMed
  463. Lerman A, Hildebrand FL Jr, Aarhus LL, Burnett JC Jr. Endothelin has biological actions at pathophysiological concentrations. Circulation. 1991 May; 83 (5):1808-14
    View PubMed
  464. Perrella MA, Margulies KB, Wei CM, Aarhus LL, Heublein DM, Burnett JC Jr. Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs. J Clin Invest. 1991 May; 87 (5):1649-55
    View PubMed
  465. Margulies KB, Heublein DM, Perrella MA, Burnett JC Jr. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol. 1991 Apr; 260 (4 Pt 2):F562-8
    View PubMed
  466. Lerman A, Click RL, Narr BJ, Wiesner RH, Krom RA, Textor SC, Burnett JC Jr. Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. Transplantation. 1991 Mar; 51 (3):646-50
    View PubMed
  467. Taliercio CP, Vlietstra RE, Ilstrup DM, Burnett JC, Menke KK, Stensrud SL, Holmes DR Jr, Holmes DR Jr. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol. 1991 Feb; 17 (2):384-90
    View PubMed
  468. Underwood RD, Chan DP, Burnett JC, Jr. Endothelin: an endothelium-derived vasoconstrictor peptide and its role in congestive heart failure. Heart Failure. 1991; 7:50-8.
  469. Margulies KB, Perrella MA, Heublein DM, Burnett JC Jr. ANF-mediated renal cyclic GMP generation in congestive heart failure. AN J PHYSIOL. 1991; 260:F562-8.
  470. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Endotheline circulate et tissulaire dans l'atherosclerose grave. Le Journal International De Medecine. 1991; 214:27-33.
  471. Edwards BS, Rodeheffer RJ, Reeder GS, Burnett JC Jr. Expression of atrial natriuretic factor in the human ventricle is independent of chamber dilation. J Am Coll Cardiol. 1990 Dec; 16 (7):1589-93
    View PubMed
  472. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation. 1990 Dec; 82 (6):2226-30
    View PubMed
  473. Winaver J, Burnett JC, Tyce GM, Dousa TP. ANP inhibits Na(+)-H+ antiport in proximal tubular brush border membrane: role of dopamine. Kidney Int. 1990 Dec; 38 (6):1133-40
    View PubMed
  474. Margulies KB, McKinley LJ, Cavero PG, Burnett JC Jr. Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure. Kidney Int. 1990 Dec; 38 (6):1101-8
    View PubMed
  475. Lerman A, Hildebrand FL Jr, Margulies KB, O'Murchu B, Perrella MA, Heublein DM, Schwab TR, Burnett JC Jr. Endothelin: a new cardiovascular regulatory peptide. Mayo Clin Proc. 1990 Nov; 65 (11):1441-55
    View PubMed
  476. Miller TD, Rogers PJ, Bauer BA, Burnett JC Jr, Bailey KA, Bove AA. What stimulates atrial natriuretic factor release during exercise? J Lab Clin Med. 1990 Oct; 116 (4):487-91
    View PubMed
  477. Sanchez-Ferrer CF, Burnett JC Jr, Lorenz RR, Vanhoutte PM. Possible modulation of release of atrial natriuretic factor by endothelium-derived relaxing factor. Am J Physiol. 1990 Sep; 259 (3 Pt 2):H982-6
    View PubMed
  478. Loftus JP, Redfield MM, Burnett JC Jr. Atrial natriuretic factor inhibits hypertonic saline-mediated decreases in renal hemodynamics. Kidney Int. 1990 Aug; 38 (2):227-31
    View PubMed
  479. Cavero PG, Miller WL, Heublein DM, Margulies KB, Burnett JC Jr. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol. 1990 Aug; 259 (2 Pt 2):F312-7
    View PubMed
  480. Margulies KB, Cavero PG, Seymour AA, Delaney NG, Burnett JC Jr. Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factor. Kidney Int. 1990 Jul; 38 (1):67-72
    View PubMed
  481. Cavero PG, Margulies KB, Winaver J, Seymour AA, Delaney NG, Burnett JC Jr. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation. 1990 Jul; 82 (1):196-201
    View PubMed
  482. Margulies KB, Burnett JC Jr. Atrial natriuretic factor modulates whole kidney tubuloglomerular feedback. Am J Physiol. 1990 Jul; 259 (1 Pt 2):R97-101
    View PubMed
  483. Abassi Z, Haramati A, Hoffman A, Burnett JC Jr, Winaver J. Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure. Am J Physiol. 1990 Jul; 259(1 Pt 2):R84-9.
    View PubMed
  484. Khraibi AA, Heublein DM, Burnett JC Jr, Knox FG. Renal interstitial hydrostatic pressure and ANF in exaggerated natriuresis of the SHR. Am J Physiol. 1990 Jun; 258 (6 Pt 2):R1380-5
    View PubMed
  485. Miller WL, Burnett JC Jr. Blood vessel physiology and pathophysiology. Rheum Dis Clin North Am. 1990 May; 16(2):251-60.
    View PubMed
  486. Khraibi AA, Heublein DM, Burnett JC Jr, Knox FG. Dissociation of renal interstitial hydrostatic pressure and natriuresis of atrial natriuretic factor. Am J Physiol. 1990 Feb; 258 (2 Pt 2):R481-6
    View PubMed
  487. Hildebrand FL Jr, Burnett JC Jr. Endothelin at pathophysiologic concentrations is a potent renal vasoconstrictor resistant to atrial natriuretic factor. J Am Coll Cardiol. 1990 Feb; 15(Suppl A):156A.
  488. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990 Jan; 258 (1 Pt 2):F115-20
    View PubMed
  489. Miller WL, Edwards BS, Zimmerman RS, Burnett JC Jr. Renal-endocrine adaptations to endogenous atrial natriuretic factor during tachycardia-induced reductions in renal perfusion pressure. Circ Res. 1990 Jan; 66 (1):76-83
    View PubMed
  490. Winaver J, Burnett JC, Jr.. Neurohumoral and renal mechanisms in heart failure. Current Opin In Cardiol. 1990; 5:278-84.
  491. Cavero PG, Margulies KB, Winaver JM, Seymour AA, Delaney NB, Burnett JC, Jr.. Renal tubular action of neutral endopeptidase inhibition in congestive heart failure (CHF). Kidney Int. 1990; 37(1):337.
  492. Burnett JC, Gersh BJ. Cardiac Failure: An Overview. Curr Opin Cardiol. 1990; 5:269-70.
  493. Lee ME, Miller WL, Edwards BS, Burnett JC Jr. Role of endogenous atrial natriuretic factor in acute congestive heart failure. J Clin Invest. 1989 Dec; 84 (6):1962-6
    View PubMed
  494. Schaff HV, Mashburn JP, McCarthy PM, Torres EJ, Burnett JC. Natriuresis during and early after cardiopulmonary bypass: relationship to atrial natriuretic factor, aldosterone, and antidiuretic hormone. J Thorac Cardiovasc Surg. 1989 Nov; 98(5 Pt 2):979-86.
    View PubMed
  495. Burnett JC Jr. Hypertension and renal disease among minorities. Genetic defect may increase susceptibility in blacks. Nephrol News Issues. 1989 Nov; 3(11):17-8.
    View PubMed
  496. Miller VM, Komori K, Burnett JC Jr, Vanhoutte PM. Differential sensitivity to endothelin in canine arteries and veins. Am J Physiol. 1989 Oct; 257 (4 Pt 2):H1127-31
    View PubMed
  497. Burnett JC Jr, Osborn MJ, Hammill SC, Heublein DM. The role of frequency of atrial contraction versus atrial pressure in atrial natriuretic peptide release. J Clin Endocrinol Metab. 1989 Oct; 69 (4):881-4
    View PubMed
  498. Redfield MM, Edwards BS, Heublein DM, Burnett JC Jr. Restoration of renal response to atrial natriuretic factor in experimental low-output heart failure. Am J Physiol. 1989 Oct; 257 (4 Pt 2):R917-23
    View PubMed
  499. Redfield MM, Edwards BS, McGoon MD, Heublein DM, Aarhus LL, Burnett JC Jr. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation. 1989 Sep; 80 (3):651-7
    View PubMed
  500. Schini VB, Hendrickson H, Heublein DM, Burnett JC Jr, Vanhoutte PM. Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol. 1989 Jun 20; 165 (2-3):333-4
    View PubMed
  501. Burnett JC Jr. Atrial natriuretic factor: implications in congestive heart failure and hypertension. J Hum Hypertens. 1989 Jun; 3(Suppl 1):41-6.
    View PubMed
  502. Torres VE, Wilson DM, Offord KP, Burnett JC Jr, Romero JC. Natriuretic response to volume expansion in polycystic kidney disease. Mayo Clin Proc. 1989 May; 64 (5):509-15
    View PubMed
  503. Redfield MM, Burnett JC Jr. Atrial natriuretic factor in congestive heart failure: Pathophysiology and therapeutic considerations. Proceedings of the symposium: Atrial Peptides and Their Novel Analogues - Royal College of Physicians London, England IBC Technical Services. 1989 Mar.
  504. Redfield MM, Burnett JC Jr. Cardiovascular action of atrial natriuretic factor. Contemp Issues Nephrol. 1989; 21:163-89.
  505. Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 1989 Jan; 83 (1):317-20
    View PubMed
  506. Gonzalez-Campoy JM, Kachelski J, Burnett JC Jr, Romero JC, Granger JP, Knox FG. Proximal tubule response in aldosterone escape. Am J Physiol. 1989 Jan; 256 (1 Pt 2):R86-90
    View PubMed
  507. Burnett JC, Jr, Osborn MJ, Hammill SC, Heublein DM. The role of atrial contraction versus atrial pressure in atrial natriuretic peptide release. J Clin Endocrinol Metab 1989 Oct; 69:881-4.
  508. Cody RJ, Massie BM, Burnett JC Jr. Roundtable discussion four. Am J Hypertens. 1988 Oct; 1(PART 2):421S-422S.
    View PubMed
  509. Burnett JC Jr. The atrial peptide system in cardiac disease. Am J Hypertens. 1988 Oct; 1 (4 Pt 2):410S-420S
    View PubMed
  510. Zimmerman RS, Ryan J, Edwards BS, Klee G, Zimmerman D, Scott N, Burnett JC Jr. Cardiorenal endocrine dynamics during volume expansion in hypothyroid dogs. Am J Physiol. 1988 Jul; 255 (1 Pt 2):R61-6
    View PubMed
  511. Taliercio CP, Burnett JC. Contrast nephropathy, cardiology and the newer radiocontrast agents. Int J Cardiol. 1988 May; 19 (2):145-51
    View PubMed
  512. Winaver J, Hoffman A, Burnett JC Jr, Haramati A. Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. Am J Physiol. 1988 May; 254(5 Pt 2):R776-84.
    View PubMed
  513. Hoffman A, Burnett JC Jr, Haramati A, Winaver J. Effects of atrial natriuretic factor in rats with experimental high-output heart failure. Kidney Int. 1988 Mar; 33(3):656-61.
    View PubMed
  514. Showalter CJ, Zimmerman RS, Schwab TR, Edwards BS, Opgenorth TJ, Burnett JC Jr. Renal response to atrial natriuretic factor is modulated by intrarenal angiotensin II. Am J Physiol. 1988 Mar; 254 (3 Pt 2):R453-6
    View PubMed
  515. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988 Feb; 62 (2):191-5
    View PubMed
  516. Torres VE, Wilson DM, Offord K, Burnett JC Jr, Romero JC. Natriuretic response to volume expansion (nrve) in adult polycystic kidney disease (APKD) with normal renal function. Kidney Int. 1988 Jan; 33:211.
  517. Edwards BS, Ackermann DM, Lee ME, Reeder GS, Wold LE, Burnett JC Jr. Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest. 1988 Jan; 81 (1):82-6
    View PubMed
  518. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Role of atrial peptide system in renal and endocrine adaptation to hypotensive hemorrhage. Am J Physiol. 1988 Jan; 254 (1 Pt 2):R56-60
    View PubMed
  519. Burnett JC Jr, Rubanyi GM, Edwards BS, Schwab TR, Zimmerman RS, Vanhoutte PM. Atrial natriuretic peptide decreases cardiac output independent of coronary vasoconstriction. Proc Soc Exp Biol Med. 1987 Dec; 186 (3):313-8
    View PubMed
  520. O'Fallon WM, Rings L, Gonzalez R, Burnett J, Golda C, Hayes G, Neveu M, O'Neill L, Zemek R. Natural History Study of Congenital Heart Defects. Control Clin Trials. 1987 Dec; 8(4 Suppl):115S-120S.
    View PubMed
  521. Arend LJ, Bakris GL, Burnett JC Jr, Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. Journal of Laboratory & Clinical Medicine. 1987 Oct; 110(4):406-11.
    View PubMed
  522. Zachariah PK, Burnett JC Jr, Ritter SG, Strong CG. Atrial natriuretic peptide in human essential hypertension. Mayo Clin Proc. 1987 Sep; 62(9):782-6.
    View PubMed
  523. Zimmerman RS, Schirger JA, Edwards BS, Schwab TR, Heublein DM, Burnett JC Jr. Cardio-renal-endocrine dynamics during stepwise infusion of physiologic and pharmacologic concentrations of atrial natriuretic factor in the dog. Circ Res. 1987 Jul; 61(1):63-9.
    View PubMed
  524. Granger JP, Burnett JC Jr, Romero JC, Opgenorth TJ, Salazar J, Joyce M. Elevated levels of atrial natriuretic peptide during aldosterone escape. Am J Physiol. 1987 May; 252(5 Pt 2):R878-82.
    View PubMed
  525. Khraibi AA, Granger JP, Burnett JC Jr, Walker KR, Knox FG. Role of atrial natriuretic factor in the natriuresis of acute volume expansion. Am J Physiol. 1987 May; 252(5 Pt 2):R921-4.
    View PubMed
  526. Zimmerman RS, Edwards BS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial natriuretic peptide during mineralocorticoid escape in the human. J Clin Endocrinol Metab. 1987 Mar; 64:624-627.
    View PubMed
  527. Zimmerman RS, Edwards BS, Schwab TR, Heublein DM, Burnett JC Jr. Cardiorenal-endocrine dynamics during and following volume expansion. Am J Physiol. 1987 Feb; 252(2 Pt 2):R336-40.
    View PubMed
  528. Zimmerman RS, Gharib H, Zimmerman D, Heublein D, Burnett JC Jr. Atrial natriuretic peptide in hypothyroidism. J Clin Endocrinol Metab. 1987 Feb; 64(2):353-5.
    View PubMed
  529. Edwards BS, Zimmerman RS, Burnett JC Jr. Atrial natriuretic factor: physiologic actions and implications in congestive heart failure. Cardiovasc Drugs Ther. 1987; 1 (1):89-100
    View PubMed
  530. Salazar FJ, Granger JP, Joyce ML, Burnett JC Jr, Bove AA, Romero JC. Effects of hypertonic saline infusion and water drinking on atrial peptide. Am J Physiol. 1986 Dec; 251(6 Pt 2):R1091-4.
    View PubMed
  531. Edwards BS, Schwab TR, Zimmerman RS, Heublein DM, Jiang NS, Burnett JC Jr. Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension. Circ Res. 1986 Dec; 59(6):663-7.
    View PubMed
  532. Schwab TR, Edwards BS, DeVries WC, Zimmerman RS, Burnett JC Jr. Atrial endocrine function in humans with artificial hearts. N Engl J Med. 1986 Nov 27; 315(22):1398-401.
    View PubMed
  533. Bakris GL, Wilson DM, Burnett JC Jr. The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol. Circulation. 1986 Nov; 74(5):1061-5.
    View PubMed
  534. Ackermann DM, Edwards BS, Wold LE, Burnette JC Jr. Atrial natriuretic peptide: localization in the human heart. JAMA. 1986 Aug 22-29; 256(8):1048.
    View PubMed
  535. Schwab TR, Edwards BS, Heublein DM, Burnett JC Jr. Role of atrial natriuretic peptide in volume-expansion natriuresis. Am J Physiol. 1986 Aug; 251(2 Pt 2):R310-3.
    View PubMed
  536. Edwards BS, Ackermann DM, Schwab TR, Heublein DM, Edwards WD, Wold LE, Burnett JC Jr. The relationship between atrial granularity and circulating atrial natriuretic peptide in hamsters with congestive heart failure. Mayo Clin Proc. 1986 Jul; 61(7):517-21.
    View PubMed
  537. Burnett JC Jr, Opgenorth TJ, Granger JP. The renal action of atrial natriuretic peptide during control of glomerular filtration. Kidney Int. 1986 Jul; 30(1):16-9.
    View PubMed
  538. Granger JP, Opgenorth TJ, Salazar J, Romero JC, Burnett JC Jr. Long-term hypotensive and renal effects of atrial natriuretic peptide. Hypertension. 1986 Jun; 8(6 Pt 2):II112-6.
    View PubMed
  539. Opgenorth TJ, Burnett JC Jr, Granger JP, Scriven TA. Effects of atrial natriuretic peptide on renin secretion in nonfiltering kidney. Am J Physiol. 1986 May; 250(5 Pt 2):F798-801.
    View PubMed
  540. Taliercio CP, Vlietstra RE, Fisher LD, Burnett JC. Risks for renal dysfunction with cardiac angiography. Ann Intern Med. 1986 Apr; 104(4):501-4.
    View PubMed
  541. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986 Mar 7; 231(4742):1145-7.
    View PubMed
  542. Salazar FJ, Romero JC, Burnett JC Jr, Schryver S, Granger JP. Atrial natriuretic peptide levels during acute and chronic saline loading in conscious dogs. Am J Physiol. 1986; 251:R499-503.
    View PubMed
  543. Salazar FJ, Fiksen-Olsen MJ, Opgenorth TJ, Granger JP, Burnett JC Jr, Romero JC. Renal effects of ANP without changes in glomerular filtration rate and blood pressure. Am J Physiol. 1986; 251:F532-6.
    View PubMed
  544. Scriven TA, Burnett JC Jr. Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation. 1985 Oct; 72(4):892-7.
    View PubMed
  545. Burnett JC Jr, Haas JA, Larson MS. Renal interstitial pressure in mineralocorticoid escape. Am J Physiol. 1985 Sep; 249(3 Pt 2):F396-9.
    View PubMed
  546. Granger JP, Opgenorth TO, Burnett JC Jr. Atrial natriuretic factor-induced natriuresis without increases in glomerular filtration rate in the sodium-depleted dog. Clin Res. 1985 Apr; 33(PART 1):485.
  547. Bakris GL, Burnett JC Jr. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985 Feb; 27(2):465-8.
    View PubMed
  548. Burnett JC Jr, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 1984 Nov; 247(5 Pt 2):F863-6.
    View PubMed
  549. Mertz JI, Haas JA, Berndt TJ, Burnett JC Jr, Knox FG. Effects of bradykinin on renal interstitial pressures and proximal tubule reabsorption. Am J Physiol. 1984 Jul; 247(1 Pt 2):F82-5.
    View PubMed
  550. Mertz JI, Haas JA, Berndt TJ, Burnett JC Jr, Knox FG. Effects of secretin on peritubular capillary physical factors and proximal fluid reabsorption in the rat. J Clin Invest. 1983 Aug; 72(2):622-5.
    View PubMed
  551. Knox FG, Mertz JI, Burnett JC Jr, Haramati A. Role of hydrostatic and oncotic pressures in renal sodium reabsorption. Circ Res. 1983 May; 52(5):491-500.
    View PubMed
  552. Hartupee DA, Burnett JC Jr, Mertz JI, Knox FG. Acetylcholine-induced vasodilation without natriuresis during control of interstitial pressure. Am J Physiol. 1982 Oct; 243(4):F325-9.
    View PubMed
  553. Burnett JC Jr, Haas JA, Knox FG. Segmental analysis of sodium reabsorption during renal vein constriction. Am J Physiol. 1982 Jul; 243(1):F19-22.
    View PubMed
  554. Burnett JC Jr, Knox FG. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol. 1980 Apr; 238(4):F279-82.
    View PubMed
  555. Knox FG, Burnett JC Jr, Kohan DE, Spielman WS, Strand JC. Escape from the sodium-retaining effects of mineralocorticoids. Kidney Int. 1980 Mar; 17(3):263-76.
    View PubMed